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CHAPTER 1 
 
RESEARCH OVERVIEW 
This chapter provides a concise account of this dissertation.  The research objectives (see Figure 1) 
were driven with a broader motivation to provide scientific solutions for real world issues related 
to health and energy applications.  In the first branch (see Figure 1), array based optical imaging 
and electrochemical methodologies to provide constructive insights for a drug development process 
were investigated. In the second branch, the implications of nanostructure bioelectrode 
architectures for catalytic applications were investigated. 
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1.1  Research Foci on Biomedical Applications 
The time to develop a pharmaceutical drug and bring it to the market takes on average 12.5 years 
and billions of dollars. This is a laborious multi-phase process, which involves discovering 
druggable targets, performing pre-clinical and clinical studies, obtaining regulatory certifications 
and initiating the manufacturing process (Figure 2).1-3  
 
 
 
 
 
 
Figure 2. Drug development process, length and cost4 (source: Pharmaceutical Research and 
Manufacturers of America). 
 
As part of the research described in this dissertation, analytical knowledge gained in these studies 
has provided better scientific intuitions to various stages of the drug development process.  
1.1.1 Cancer Target Identification and Inhibition by Small Molecule Drugs (see Chapter 2)  
Cancer target identification and anticancer drug development have gained an attention in 
biomedical pre-clinical research.5   A surface plasmon resonance imaging (SPRi) microarray-
platform has been developed in the research described in this dissertation to study druggable cancer 
protein-protein interactions with binding kinetics.6 In vitro interactions involving tumor suppressor 
p53 and its negative regulator murine double minute 2 (MDM2) 7 was successfully imaged on a 16 
Drug target 
identification 
and Drug 
discovery
Pre-
clinical 
studies
Clinical trials
(phase I, II and III)
Regulatory 
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(FDA)
Manufacturing
10000 - 15000 
Compounds 
250 
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3 – 6 Years 6 – 7 Years 0.5 – 2 Years 
Average cost: 2.6 $ billion     Duration:  10 Years 
1 Compound 
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spot SPRi multi-array chip with high sensitivity and specificity over mutant controls. This imaging 
array platform involved a rapid microfluidic system attached to the SPR imager and a single step 
immobilization of p53 transactivational domain (TAD) peptides on the gold surface (see Figure 3) 
as self-assembled monolayers (SAMs).  Different nanomolar to micromolar concentrations of an 
MDM2 oncoprotein in a buffer solution was allowed to bind to the surface of p53 TAD. Real time 
percentage reflectivity changes of the array spots upon the interaction of MDM2 to surface p53 
TAD were monitored and used for calculating apparent binding kinetics.  Additionally, the 
inhibition of MDM2-p53 interaction by Nutlin-3a (a potential drug in a clinical stage) was also 
measured. Moreover, molecular level mass changes were obtained using a quartz crystal 
microbalance (QCM).  It is envisioned that an imaging array combined with a mass sensor could 
be used to quantitatively study any protein-protein interactions and to screen for both binding and 
potency evaluations of small molecules. 
 
Figure 3. Micro array imager for the identification of cancer protein interactions and their 
inhibition by small molecule drugs. 
 
1.1.2 Potential Driven, Microsomal Drug Metabolite synthesis and Inhibition Assays (see 
Chapter 3) 
Aside from the target identification, the most prominent burden of the drug development process 
is the pre-clinical screening process, which ensures the effectiveness and safety of the drug.  During 
this screening process, how a drug works; which chemical products (metabolites) are formed; and 
whether it is safe enough to be tested in humans are evaluated. Therefore, examining the metabolic 
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fate of drugs is an essential part of the drug development process. Metabolism is a course of 
biotransformation of drugs into different chemical entities, prominently through liver enzymatic 
reactions.   It is a natural activity in our body to increase drug hydrophilicity and decrease toxicity.8 
However, in some cases, drugs can produce reactive metabolites, which are harmful and toxic for 
biological systems. Related to the pharmaceutical industry, the efficacy and beneficial properties 
of a drug depend on the biological activity of the metabolites formed in the liver. Therapeutic or 
toxic properties of those metabolites should be investigated sensibly since the toxicity or side 
effects of a drug can counteracts its therapeutic effectiveness. Therefore, all synthetic drugs should 
be screened through liver mimics under in-vitro conditions before any drug is subjected to clinical 
studies.  
Membrane bound enzymes in hepatocytes (liver cells) govern the majority of metabolic reactions 
(hydrolysis, oxidation, reduction and conjugation). Human liver microsomes (HLM), which are 
subcellular fractions derived from differential centrifugation of liver homogenates, are used as rich 
source of liver enzymes (cytochrome P450s (CYPs), cytochrome P450 reductases (CPRs), carboxyl 
esterases, and UDP- glucuronosyltransferases (UGTs)) for in-vitro drug screening assays.9  
Presently, these studies are conducted using hepatic or purified liver enzyme-based biological 
assays. Longer incubation times, lower yield of drug metabolites, use of expensive NADPH 
cofactor and purified enzymes, and tedious purification protocols are some practical issues 
integrated with these conventional biological assays.10 A simple HLM based bioreactor technology 
for electrochemical drug activity assay has been developed as part of this dissertation research. 
In this preliminary study, the influence of various electrode materials on the direct electron transfer 
and electrocatalytic properties of one-step immobilized HLMs was examined.  Electrode roughness 
and surface defects were found to favor enhanced amounts of electroactive microsomal proteins, 
and the surface oxygen density of a carbon electrode influences the charge transport kinetics 
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between the electrode surface and microsomal enzymes. The CYP-specific bioactivity of the liver 
microsomal film on the electrode was confirmed by monitoring the electrocatalytic conversion of 
testosterone to 6β-hydroxytestosterone and its inhibition by the CYP-specific ketoconazole 
inhibitor (see Figure 4).  These findings provided successful implications in the design of a one-
step, electrochemical bioelectrode for drug activity and inhibition assay for preclinical drug 
development application. 
 
 
 
 
 
Figure 4. Potential driven drug metabolism by HLM 
 
1.1.3 Single Drop Electro-analysis for low-cost Quality Control Testing of Oxidative 
Pharmaceuticals (see Chapter 4) 
Quality control analysis of drugs for their active pharmaceutical ingredients (APIs) is an important 
process in drug manufacturing.11 The applicability of screen-printed electrodes was validated as a 
cost-effective and instant analytical tool in the quality assurance process of oxidative drugs to 
quantify active pharmaceutical ingredients.  Electroanalysis of oxidative pharmaceuticals as single 
50 µL drops on screen printed electrodes (SPEs) modified with carboxylated multi-walled carbon 
nanotubes was demonstrated (see Figure  5) with low limits of detection and high sensitivity 
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expressed in nA current per µM analyte.  It was determined that chemical structure, molecular size, 
and polar/nonpolar properties contribute significantly to the interaction of a single drop of analyte 
with the electrode surface to facilitate interfacial charge transport, and thus the oxidation current. 
This approach was tested using commercially available model pharmaceuticals with percentage 
recovery in the range of 92-99%.  These successful findings suggest the applicability of a single 
drop electroanalysis as a cost-effective and instant analytical tool for the quality assurance (QA) 
process in the pharmaceutical industry, especially to determine the purity of a drug. 
 
 
 
 
 
 
 
 
 
Figure 5. Single drop electroanalysis on a screen printed electrode (WE- working electrode, CE-
counter electrode, and RE- reference electrode). 
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1.2 Research Foci on Bio-electrocatalysis 
1.2.1 Nanostructure Electrode Architectures for Bioelectronics (see Chapters 5 and 6) 
Novel bioelectronics rely on the surface design of electrodes to sustain active redox enzymes with 
good stability and electronic connectivity.11-13 It has been demonstrated in the dissertation research 
that tailoring of the electrode with carbon nanostructure modifications can facilitate the controlled 
immobilization of redox enzymes and offer enhanced direct electron transfer electrocatalytic 
properties.14 One study performed as part of the dissertation research proposed that edge plane, 
pyrolytic graphite electrodes plays an important role in exposing a large proportion of the basal 
planes of the carbon nanotubes to allow enhanced π-π stacking of a pyrenyl compound and 
subsequent high density protein immobilization yielding large electrocatalytic currents (see Figure 
6). 
 
 
 
 
 
 
 
 
Figure 6. Proposed electrode effect on carbon nanotube orientation. 
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Another study described in this dissertation showed an unprecedented peroxide reduction current 
density by MP-11 (an 11-amino acid heme-iron peptide) immobilized on the similar nanostructure 
design (see Figure 7). Electrocatalytic activities of large, fragile, redox-center buried, or otherwise 
difficult to study metalloenzymes can be overcome by changing the proteins into small 
catalytically-active redox domains that can effectively connect with the electrodes. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Covalent immobilization of MP-11 onto pyrenyl carbon-nanostructures. 
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CHAPTER 2 
 
 
LABEL-FREE REAL-TIME MICROARRAY IMAGING OF CANCER PROTEIN-PROTEIN 
INTERACTIONS AND THEIR INHIBITION BY SMALL MOLECULES 
 
2.1 Introduction 
In addition to important biological roles, protein-protein interactions (PPIs) are known to block 
cellular defenses against diseases such as cancer. Thus, targeting oncogenic PPIs for the 
development of small molecule therapeutics has become a hot research topic.1-3 One such PPI is 
be-tween p53, a tumor suppressor protein and transcriptional factor that plays an important role in 
cell cycle arrest, apoptosis, DNA repair, differentiation, and senescence,4 and the oncoprotein 
murine double minute 2 (MDM2, an analogue of human double minute 2 protein),5 which inhibits 
p53. In many tumors, overexpression of MDM2 has been shown to block the function of p53 and 
promote tumor progression. Numerous research groups have developed methods to detect 
biomolecules and study PPIs. For example, Corn and co-workers developed a 16-spot array for 
detection of genomic materials, proteins, and on-chip enzymatic reac-tions,6,7 and Kim et al. 
characterized the binding of the yeast GAL4 dimerization domain to GAL11 protein, which is 
involved in galactose metabolism, using a chip-based cell cultivation system integrated with the 
SPRi technique.8  
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Using an SPR method, Domenici et al. found that the interaction of the bacterial protein azurin with 
p53 modulates MDM2–p53 binding.9 Quantitative screening of small molecule G4 ligands on a G-
quadruplex was also investigated using the SPRi technique.10 Chen et al. demonstrated real-time 
monitoring of antibody-polypeptide binding as a drug screening platform using an SPRi microarray 
chip.11 The interaction between human papillomavirus (HPV) E7 protein and retinoblastoma tumor 
suppressor protein (RB) was investigated for potential inhibition by an RB binding peptide (PepC) 
using an SPRi system.12 Vassilev et al. analyzed small molecule-mediated inhibition of MDM2 
binding to p53 using a conventional SPR assay method.13 Recently, macrocyclic organopeptide 
hybrid inhibitors of the MDM2-p53 interaction were assessed by an SPR inhibition assay.14,15  
Relevant to the importance of rapid small molecule screening arrays to inhibit cancer PPIs, an SPR 
imaging of cancer PPIs and their inhibition by small molecule drugs along with real-time binding 
kinetics determined for the same sample in a single assay wered presented. The microarray imaging 
feature of SPR over conventional non-imaging methods has the following advantages: (i) SPRi 
offers simplicity and relatively better throughput than conventional single or dual channel SPR. 
Thus, shorter assay times with enhanced precision of analytical data are available; (ii) An image-
based bioanalytical approach allows easy interpretation of results useful for rapid biosensing and 
screening applications; (iii) SPRi allows measurements of mutlianalytes and multiple 
concentrations along with controls in a single measurement; and (iv) In addition to the rapid 
imaging feature of SPRi, one can obtain real time refractive index changes (association and 
dissociation curves) for all spots in the microarray and thus measure fundamental binding kinetics 
of any biological interaction (for e.g., protein-protein, antibody-antigen, nucleotide-protein, 
nucleotide-nucleotide, ligand-receptor, cell-cell, cell-biomolecule, and biomolecule-small 
molecule interactions).16,17 
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In this study, additional quantitative information were obtained by combining SPRi with a quartz 
crystal microbalance (QCM). Specifically, the interaction between p53 and MDM2 was utilized as 
a model system, because blocking the MDM2-p53 interaction by small molecules has been 
identified as a promising therapeutic strategy for cancer treatment.18-20 To assess the specificity of 
the SPRi signals for MDM2 binding and drug inhibition assays, both the wild-type and mutant 
forms of p53 trans-activation domains (TADs) were examined. 
Figure 1 shows the strategy for imaging cancer protein interactions and inhibition of these 
interactions by small molecules, providing binding kinetics and quantitative information.  
 
 
 
 
 
 
Figure 1. Schematic representation of SPRi and QCM strategies for detection of the MDM2-p53 
TAD interaction and its inhibition by small molecules (MDM2 PDB: 1YCR). 
 
p53 TAD peptides were immobilized as self-assembled monolayers (SAMs) on gold surfaces of 
both SPRi microarray chips and gold-coated quartz crystal resonators. The interaction of added 
MDM2 solution to surface p53 TAD was investigated by measuring the pixel intensity increase in 
SPRi and the frequency decrease (mass addition) in QCM. Rapid, label-free and real-time 
microarray analysis of PPIs with simplicity is preferred over other time consuming, tedious 
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analytical methods. Moreover, a microarray platform that can also provide binding kinetics and 
selectivity and allow detection of small molecule inhibitors with inhibition efficiency parameter 
has the potential to significantly advance the present paradigm of studying important cancer and 
other disease-related PPIs and screening of small molecule drugs. Such approaches are expected to 
accelerate subsequent cell based in vitro studies and the results of which can allow further in vivo 
evaluations of potential drug candidates. 
2.2 Experimental 
2.2.1 Materials 
Wild-type (CSQETFSDLWKLLPEN, 1910.1 Da) and mutant (CSQETASDAAKLLPEN, 1676.8 
Da) peptides of p53 TAD (15-29 aa), custom designed with an added free cysteine at the end of 
each peptide sequence, were purchased from Biomatik (Ontario, Canada). Nutlin-3a was purchased 
from Cayman Chemical Company (Ann Arbor, MI) and O-Methyl-heptaethylene glycol (mPEG-
7) polymer was purchased from Polypure (Oslo, Norway). All other analytical grade chemicals 
were purchased from Sigma. 
2.2.2 Expression and Purification of Recombinant MDM2  
The expression and purification of the p53-binding N-terminal domain of MDM2 (17-125 amino 
acids, 12.5 kDa) was performed similar to the reported literature.13 Briefly, E. coli BL21 (DE3) 
cells (Stratagene Inc., CA, USA), containing the MDM2 construct with an N-terminal 6 x His tag, 
was grown in Luria-Bertani nutrient medium with 50 µg mL-1 kanamycin at 37 ºC until OD600 
reached 0.7. Then, 1 mM of isopropyl β-thiogalactopyranoside (IPTG) was added to the medium 
to induce MDM2 expression at 18 ºC overnight. Cells were harvested by centrifugation at 6000 g 
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for 20 min at 4 ºC and suspended in buffer A (20 mM Tris pH 7.0, 20 mM imidazole, 500 mM 
sodium chloride, 10 % glycerol).   
The cells were lysed by a high-pressure homogenizer and centrifuged at 20,000 g for 30 min to 
remove insoluble debris. The supernatant containing MDM2 was loaded onto a Ni-NTA column 
(GE Healthcare). After washing with 100 mL of buffer A, the purified MDM2 was eluted with 
buffer B (20 mM Tris pH 7.0, 250 mM imidazole, 500 mM sodium chloride, 10% glycerol) and 
further purified by a gel filtration column (Superdex 200, GE Healthcare) with buffer C (50 mM 
sodium phosphate pH 7.0, 100 mM sodium chloride). Gel filtration fractions corresponding to the 
MDM2 elution peaks were collected and stored frozen as aliquots of small volumes at -80 oC until 
use. The purity of the prepared MDM2 protein was confirmed by the standard polyacrylamide gel 
electrophoresis (SDS-PAGE) experiment.21 By following the above described isolation and 
purification procedures, about 6 mg of purified MDM2 (> 98% purity, SDS-PAGE, see Figure 2) 
per liter of culture was obtained. 
Figure 2. SDS-PAGE analysis of purified fractions of 
MDM2 from a gel filtration column (12.5 kDa size for 
monomer, Lanes 1-5). Lane 6 corresponds to standard 
molecular weight markers. 
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2.2.4 Preparation of SPRi Chips 
Both the wild and mutant types of p53 peptides were separately immobilized as self-assembled 
monolayers (SAMs) on 16-spot, gold SPRi array chips. The SAMs were formed between the gold 
surface and cysteinyl thiol end groups of each p53 peptide by manually spotting 450 nL (per spot) 
of the respective peptide solutions (1.0 mg mL-1 in pH 7.4 phosphate buffer) using a pipette 
dispenser and incubating for 3 h at 4 ᵒC inside a moisturized chamber to avoid drying of the 
samples. To reduce non-specific binding, p53-immobilized, gold surfaces were incubated with 
mPEG-7 blocking polymer (1% in pH 7.4 phosphate buffer) for 30 minutes. A series of drug 
solutions were prepared by diluting 1 mg mL-1 of stock solution of Nutlin-3a (1.72 mM) in 
dimethylformamide (DMF) for the inhibition study.  
2.2.4 SPRi Measurements 
Real time SPRi experiments were performed using a GWC SPRimager-II attached to a Pico Plus 
Elite Pump11 (Harvard apparatus, MA, USA) and a dual injector valve (Rheodyne Model 9725i 
PEEK injector, IDEX Health & Science LLC, CA, USA).  The sample loop volume was 100 µL. 
Both the running and sample buffers were with 10 mM phosphate buffer, pH 7.4. SPRi chips were 
fabricated containing both the wild-type and mutant p53 TAD peptides (8 spots each) within a 
single microarray to assess selectivity. Additionally, drug-free and Nutlin-3a-incubated MDM2 
samples were injected onto SPRi array spots featuring either the surface immobilized wild-type or 
the mutant p53 TAD peptide. Percentage reflectivity change (Δ%R) from the MDM2-p53 
interaction and inhibition by a small molecule were recorded in real time. Finally, difference images 
(difference between pre- and post-binding events) were processed through ImageJ software to 
obtain 3D representations of the net changes from interaction or inhibition.22 
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2.2.5 QCM Analysis 
The frequency change due to the interaction of surface p53 peptide with added MDM2 in buffer 
was validated with quantitative information using a QCM (Gamry Instruments, Warminster, PA, 
USA). The Sauerbrey equation was used to estimate the amount of bound molecules per unit 
geometric area of a QCM gold substrate, which is analogous to the SPRi microarray gold surface 
and thus justifies the validation.23, 24 
∆f = −
2𝑓0
2 
𝐴√µρ
∆m 
where Δf = frequency decrease due to mass change; fo = fundamental oscillation frequency of the 
quartz crystal (10 MHz in our case); A = geometric area of Au-surface (0.2 cm2); ρ = density of 
quartz (2.648 g cm-3), μ = shear modulus of quartz (2.947 x 1011 dyn cm-2), and Δm = mass change 
(g). 
2.3 Results and Discussion 
The three amino acid residues of p53 (so called “hot spots”), Phe19, Trp23, and Leu26, have been 
shown to offer the maximum binding energy for the interface formation between p53 and MDM2 
binding domains.25 Specificity of the MDM2-p53 interaction was investigated by examining a 
mutated p53 TAD peptide immobilized as a SAM on an SPRi microarray chip. To generate the 
mutant, the wild-type p53 TAD was mutated to alanine at the most destructive Phe19, Leu22, and 
Trp23 residues as reported in the literature26 (mutated p53 TAD was custom prepared from 
Biomatik, Ontario, Canada). In the SPRi chip, eight gold array spots in the C1 and C2 columns 
were immobilized with the mutant p53 TAD peptide, and the remaining eight spots were 
immobilized with the wild-type p53 TAD peptide (see labels in Figure 3A). A blocking step was 
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conducted using mPEG-7 as described in the methods. MDM2 solutions (10 μM) then were passed 
over the wild-type and mutant p53 spots via a microfluidic flow channel. The mutant p53 TAD 
peptides were considered to be negative controls.  
Figure 3A shows the raw difference image (difference between pre- and post-binding events), and 
Figure 3B is the corresponding 3D representation. Wild-type p53 exhibited 3.5-times greater 
reflectivity change (Δ%R) than the mutated p53 array spots (see Figures 3C and 3D) upon MDM2 
binding in the real-time analysis. Mutations of the wild type p53 TAD at predetermined amino acids 
has been shown to diminish the binding conformation required for MDM2 binding due to 
energetically unfavorable interactions.27 In agreement with this, the designed p53 peptide array chip 
and SPRi detection method exhibit excellent specificity for studying and identifying similar cancer 
PPIs. 
Figure 3. (A) SPR difference 
image, (B) 3D representation of 
the SPR difference image, (C) 
line profile of row 3 in A (R3), 
and (D) real-time average (Avg) 
responses from each of the eight-
array spots for MDM2 binding 
(10 μM) to surface wild-type p53 
peptide (C3 and C4 array spots) 
or mutated p53 (C1 and C2 array 
spots). MDM2 solution flow rate 
used was 50 μL min–1. Label a': 
point of sample injection; label 
b': onset of rinse in buffer. 
 
As another comparison, mutated p53 peptides were replaced with 1% bovine serum albumin (BSA, 
see Figure 4A, C1 and C2 array spots) and compared for the binding signals of MDM2 with wild-
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type p53 TAD (see Figure 4A, C3 and C4 array spots). Significant signal enhancement was 
observed only for the MDM2-p53 interaction and not for the MDM2-surface BSA interaction, 
which further confirmed the specificity of the microarray approach (see Figures 4C and 4D). In 
addition, it was noted that such specific PPIs can be monitored even at a high MDM2 solution flow 
rate of 100 μL min–1.  
Figure 4. (A) SPR difference image, 
(B) 3D representation of the SPR 
difference image, (C) line profile of 
row 2 in A (R2), and (D) average of the 
real time sensograms of MDM2 
binding (10 μM) to wild-type p53 array 
spots (C3 and C4 columns) or to BSA 
array spots (C1 and C2 columns). 
MDM2 solution flow rate used was 100 
μL min–1. Label a': point of sample 
injection; label b': onset of rinse in 
buffer.  
 
 
Small peptides with Cys end groups have been shown to form highly dense SAMs.28 Hence, it is 
feasible to attain high density SAMs of the immobilized p53 TADs in the designed microarray 
chips, and the thiol end group linkages can favorably orient the p53 peptide units to allow binding 
of significant amounts of MDM2 molecules. This should in turn offer good sensitivity of detection. 
In agreement with this, nM levels of MDM2 interaction with the surface p53 peptide SAM were 
easily detectable in the microarray (see Figure 5). The measured limit of detection (LOD) of MDM2 
was 72 nM (LOD = Mb + 3Sd, where Mb is the mean and Sd is the standard deviation of Δ%R signal 
for 0 nM MDM2 solution).29 This indicates that the designed microarray can also be used for 
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sensitive protein detection and by appropriate surface modification of the microarray, one may be 
able to further enhance the sensitivity and obtain even lower detection levels. 
 
 
 
 
 
 
 
 
Figure 5. (A) 3D representations of the SPR difference images of 4 adjacent spots and (B) 
percentage reflectivity changes for the binding interactions related to varying concentrations of 
MDM2 with (a) wild and (b) mutated types of immobilized p53 TAD peptides. 
 
Figure 5 shows the trend in responses for various nM to µM concentrations of MDM2 upon 
interaction with the surface immobilized wild-type p53 TAD peptide. Increments of pixel 
intensities of the SPR images are illustrated as 3D representations with increase in MDM2 
concentrations (see Figure 5A). The percentage reflectivity increase resulting from the MDM2-p53 
interaction was plotted against MDM2 concentrations, and the signals were saturated at 10 μM of 
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MDM2 (see Figure 5B). Real-time sensograms of each MDM2 concentration are provided in 
Figure 6. 
Figure 6. Real time percentage reflectivity changes 
for the binding interactions of varying concentrations 
of MDM2 to surface wild-type p53 TAD. MDM2 
solution flow rate of 50 μL min–1 was used in this 
experiment. Label a': point of sample injection; label 
b': onset of rinse in buffer. 
 
 
Possible high-density construction of the small p53 peptide SAM on gold surfaces of the SPRi 
microarray allowed detection of small concentrations of MDM2 with a relatively large dynamic 
range of up to 10 μM MDM2. Interaction between MDM2 and mutated p53 peptides was negligible 
at lower MDM2 concentrations, but it significantly increased at MDM2 concentrations > 1 μM, 
possibly due to non-specific interactions caused by high loading of MDM2 molecules (see Figure 
5B-b). The objective of this study was to develop a simple and rapid SPRi-based strategy to identify 
potential cancer-causing PPIs and to convert this design into an efficient drug-screening platform. 
Therefore, relatively large flow rates of samples in the microfluidics (50 to 100 μL min–1) were 
used to obtain instant results, within a few minutes, without requiring any prolonged incubation or 
tedious procedures on the microarray.  
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The inhibition of the MDM2-p53 interaction was measured by Nutlin-3a, which is a pre-clinical 
small molecule drug developed by a group of scientists at Hoffmann-La Roche in Nutley, New 
Jersey.13, 30 For the inhibition assay, different concentrations of Nutlin-3a pre-incubated with 1 μM 
MDM2 were passed over a SPRi chip fabricated with the wild type p53 (see Figure 7A).  
Figure 7. (A) Real-time percentage reflectivity changes for the binding interactions between wild-
type p53 and (a) 0 nM, (b) 100 nM, (c) 500 nM, and (d) 5 µM Nutlin-3a treated with MDM2 (1 
µM). (B) SPRi inhibition curve for the MDM2-p53 interaction. MDM2 solution flow rate of 50 μL 
min–1 was used in this experiment. Label a': point of sample injection; label b': onset of rinse in 
buffer. 
As shown in Figure 7B, Nutlin-3a competed with the MDM2-p53 interaction in a dose-dependent 
manner. The measured half-inhibitory concentration of Nutlin-3a (IC50) for the designed microarray 
method was 90 nM towards inhibiting the MDM2-p53 interaction. The measured IC50 value is in 
good agreement with those of reported studies.13,15 A notable bulk effect was observed for higher 
concentrations of Nutlin-3a solution in DMF (albeit DMF was ≤ 0.3%, Figure 7A). The inhibition 
activity was determined by measuring the difference between the final plateau region and the initial 
baseline of the real time reflectivity curves (see Figure 7). 
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These results demonstrate that SPR imaging of the MDM2-p53 interaction is simple, offers good 
throughput, is sensitive for small molecule screening, and detecting any PPIs is feasible with good 
sensitivity and selectivity. In addition to developing an imaging-based SPR method for cancer PPIs 
and inhibition assays, it was shown that one can obtain apparent binding constants from the same 
sample, thus showing multiple advantages of using SPRi. Prior to imaging the binding or inhibition 
events on the arrays, real-time reflectivity changes upon MDM2 interaction (50 μL min–1 flow rate) 
were monitored with p53 and, a 1:1 bimolecular interaction kinetic model was used to calculate 
values for apparent association rate (ka), dissociation rate (kd), and binding constant (KD).31-33 The 
apparent values for ka, kd, and KD were 342 (± 27) M–1 s–1, 8.4 (± 0.8) × 10–5 s–1, and 0.25 (± 0.03) 
µM, respectively.  
The KD provides an immediate understanding of the affinities between two interacting 
biomolecules. Reported NMR and isothermal calorimetric techniques showed KD values in the 
range of 0.4–0.6 µM for the interaction between the N-terminal p53-interacting domain of MDM2 
and p53 TAD.25, 27, 34-36 Conventional SPR measurements for the interaction of full length p53 and 
p53 TAD peptide MDM2 yielded KD values of 0.4 µM and 0.1–1.0 µM, respectively.9, 15, 37 Thus, 
the observed KD value of 0.25 µM is in reasonable agreement with prior reports based on 
bimolecular kinetics. Nonlinear regression analysis of the sigmoidal response, incorporating higher 
HDM2 concentrations to calculate KD (concentration at half-maximal SPRi response in Figure 5B), 
gave a value of 2.16 (± 0.09) µM.38-39 The disagreement of the measured KD values between the 
two models is not surprising, as this could likely result from the limitation of applying a simple 
bimolecular model (based on linear least square analysis) at higher substrate concentrations due to 
factors that break boundary conditions (for e.g., cooperativity, heterogeneity).40 
QCM experiments were carried out to validate the results obtained from the SPRi microarrays and 
to obtain quantitative information of immobilized p53 TADs, bound MDM2 molecules, and p53-
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MDM2 inhibition by Nutlin-3a. Increased mass on the gold surface of a QCM resonator by 
immobilization of molecules on the surface causes a decrease in the oscillation frequency of the 
resonator according to the Sauerbrey equation.23,41 The surface area-normalized apparent number 
of molecules bound to the gold surface of the resonator at each step of the assembly, including 
interaction and inhibition, was determined (see Table 1). It is to be noted that the calculated number 
of molecules are strictly apparent, because viscoelasticity properties and hydration of protein 
molecules are not accounted for in the estimation.42,43 Based on the reported structural 
information,25  the MDM2-p53 interaction occurs with a 1:1 stoichiometry, and it was estimated 
that approximately 56% of p53 TAD peptide molecules were in the appropriate orientation on the 
gold surface to interact with MDM2 molecules. The less than theoretically possible 100% 
interaction ratio could be due to the larger size of MDM2, which could cause sterically hindered 
access to the surrounding p53 peptide binding sites.  
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Table 1. QCM Estimation. 
 
 
 
 
 
 
For the MDM2 solution that was pre-incubated with Nutlin-3a, the decrease in oscillation 
frequency was smaller than that of the free MDM2 binding to surface p53 due to the drug-induced 
inhibition of the MDM2-p53 interaction. This effect is illustrated as a change in mass added to the 
quartz crystal in Figure 8. Mass estimations have shown that about 40% of initially-bound MDM2 
molecules are inhibited by the drug treatment when tested for a saturating MDM2 level (10 µM, 
see Figure 8) at a high concentration of Nutlin-3a (170 µM). This indicates that the surface 
chemistry of p53 peptide immobilization via a cysteinyl thiol linkage onto gold is reasonably stable 
in terms of facilitating the MDM2-p53 interaction and monitoring of a small molecule caused 
inhibition on the SPRi chip. Furthermore, the QCM estimation on the gold surface is 
complementary to the SPRi analysis.  
Assembly -∆f / Hz Apparent Number of  
molecules (x1012)  cm–2 
Au-p53 57 ± 5 80 ± 7 
Au-p53/mPEG-7 129 ± 22 1010 ± 170 
Au-p53/mPEG-7/MDM2 213 ± 24 45 ± 6  
Au-p53/mPEG-7/MDM2+Nutlin-3a 131± 13 28 ± 3 
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Figure 8. Mass increments due to the 
attachment of wild-type p53 TAD 
peptide, mPEG7 blocking step, and 10 
µM MDM2 treated with (a) 0 and (b) 170 
µM of Nutlin-3a determined by the QCM 
experiments. 
 
 
 
2.4 Conclusions 
In conclusion, the results presented above show that the SPRi technique can be used effectively to 
detect cancer PPIs and to study small molecule inhibition of PPIs in a label-free manner. 
Additionally, the real-time SPRi technique allows measurement of binding kinetics of biomolecular 
interactions related to PPIs in cancer or any other disease. Systematic screening of small molecule 
drug libraries using the SPRi microarray will aid in identification of the most efficient drug 
candidate to disrupt disease-promoting PPIs and in facilitating instant cancer drug discoveries. 
Moreover, this label-free in vitro array platform is fast, simple, robust, and offers high sensitivity 
with selectivity. The ability to use synthetic, small peptide binding domains of functional proteins 
in SPRi microarrays were demonstrated without conducting tedious whole protein purification 
techniques. The findings of this study represent a significant advancement in identification and 
characterization of biological interactions and applicability for targeted drug development. 
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CHAPTER 3 
 
 
A SIMPLE CONSTRUCTION OF ELECTROCHEMICAL LIVER MICROSOMAL 
BIOREACTOR FOR RAPID DRUG METABOLISM AND INHIBITION ASSAYS 
3.1 Introduction 
A simple construction of bioactive interfaces of human liver fractions with electrodes, which has 
the potential to transform the current paradigm of drug development by providing rapid screening 
platforms for drug metabolism and inhibition, was demonstrated in this study. Human cytochrome 
P450s (CYPs) are the major drug metabolizing enzymes present in the liver. The remarkable and 
broad catalytic properties of CYPs suggest that they may prove useful in the stereoselective green 
syntheses of fine chemicals.1,2 The in vivo catalytic activities of CYPs primarily depend on the 
electrons supplied by cytochrome P450-reductase (CPR) with NADPH acting as the electron 
source.3 The significance of the CYP-CPR interaction in altering CYP enzyme-turnover has been 
examined in several biochemical and electrochemical studies.4-7 CPR contains both flavin adenine 
dinucleotide (FAD) and flavin mononucleotide (FMN) cofactors and is the only known membrane-
bound flavoproteins. CPR transfers electrons from NADPH via FAD to FMN and further to the 
heme centers of CYPs.  In this electron transfer (ET)-pathway, phospholipd bilayers play a crucial 
role in modulating the redox potentials of FMN and FAD in CPR and aid in ET.8  
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In direct electrochemistry, the electrode acts as an electron donor to redox protein films under an 
applied negative potential.9-11 Because purification of CYPs is a tedious process, the application of 
liver microsomes or genetically engineered supersomes (microsomes specifically enriched with a 
CYP enzyme and its reductase) containing CYPs in the development of new biosensing and 
electrocatalytic systems is an emerging research area.7 Human liver microsomes (HLM) are 
obtained by homogenizing liver tissue in buffer and centrifuging the resulting slurry at 10000 x g 
to specifically isolate the major membrane-bound drug metabolizing enzymes such as CYP 
enzymes and their redox partner protein, CPR. HLM are extensively used in pharmaceutical 
industries for in vitro drug metabolism and inhibition assays and for evaluating ADME 
(Absorption, Distribution, Metabolism and Excretion) properties of any drug in development.12 
Direct ET and catalytic studies of genetically engineered microsomes,13 rat liver microsomes,14 and 
HLM15 assembled as films with polyions, microsomes coated on different thiolated hydrophobic 
gold electrodes,16 and layer-by-layer films of purified human CYPs and microsomal CPR17 have 
been conducted.  
Carbon electrodes are known for their robustness, inexpensive nature, ease of cleaning, and 
reusability. The objective of this study is to develop a suitable carbon electrode platform that will 
allow immobilization of complex HLM by direct adsorption with stability and bioactivity. Such 
analytical platform is expected to offer a novel, rapid design of HLM electrodes for drug 
metabolism assays involving simple and cost-effective electrochemical approach. In this study, 
four commonly used carbon electrodes were chosen, including basal-plane pyrolytic graphite 
(BPG), edge-plane pyrolytic graphite (EPG), glassy carbon (GC), and high purity graphite (HPG).  
 
  
31 
 
 
Considering the importance of HLM in pharmaceutical drug development and toxicology fields, 
the demonstration of a rapid, stable, and one-step microsomal bioreactor design for inexpensive 
electrochemical drug metabolism and inhibition assays is novel and highly significant. 
Additionally, the insights on the carbon electrode-dependent direct electrochemical and 
electrocatalytic properties of adsorbed HLM were demonstrated.   
3.2 Experimental 
3.2.1 Materials and Reagents 
HLM (total protein 20 mg mL–1, total CYPs 0.5 nmol mg–1 protein, NADPH-cyt c reductase activity 
154 nmol mg–1 protein min–1 that corresponds to 0.051 nmol CPR mg–1 protein,18 and cytochrome 
b5 0.34 nmol mg–1 protein) were purchased from XenoTech (Lenexa, KS, USA) and used as 
received. Disk electrodes of EPG, BPG, HPG, and GC were used in this study [geometric area 0.2 
cm2]. Pure EPG and BPG disks were constructed from PG-blocks (1 x 1 x 0.5 inches, Momentive 
Performance Materials, Albany, NY, USA). Basal planes are present parallel to the PG surface and 
edge planes are aligned perpendicular to the surface.19 HPG disks were purchased from McMaster-
Carr (POCO EDM-4 grade, Atlanta, GA, USA) and GC electrodes were obtained from CH 
Instruments (Austin, TX, USA). Testosterone, ketoconazole, and standard 6β-hydroxytestosterone 
were purchased from Sigma-Aldrich. All other reagents were high purity analytical grade.  Unless 
otherwise specified, all electrochemical measurements were carried out in phosphate buffer 
containing 0.15 M NaCl, pH 7.0 at 25 oC.  
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3.2.2 Microsomal Film Preparation  
Prior to use, all electrodes were polished and cleaned by following standard procedures to obtain 
fresh surfaces for adsorbing HLM. Briefly, BPG, EPG, and HPG disk electrodes were freshly 
polished using SiC paper (P320 grit), and GC electrodes were polished in an aqueous slurry of 
alumina (1 micron) placed on an alumina-pad (EXTEC Corp., Enfield, CT, USA) to obtain fresh 
surfaces. The polished electrodes were cleaned by ultrasonication in water for 1 min and then dried 
under nitrogen. A film of HLM was formed on each freshly polished electrode by adsorption from 
a 10 μL solution of HLM for 20 min at 4 oC. The electrodes were rinsed with buffer to remove 
weakly and unbound HLM and then used for cyclic voltammetry (CV) studies. 
3.2.3 Colorimetric Assay for Presence of Microsomal Films on Electrodes 
The presence of phospholipids in the microsomal films immobilized on various electrode surfaces 
was confirmed using a colorimetric assay. The major microsomal phospholipids, such as 
sphingomyelin, phosphatidyl serine, phosphatidyl ethanolamine, and lecithin, are the active 
components that form a red color complex with ammonium ferrothiocyanate that absorbs at ~488 
nm in chloroform as a solvent.20  
3.2.4 Fourier Transform Infrared (FTIR) Spectroscopy 
The liver microsomal films on the electrodes were characterized by FTIR spectroscopy (Nicolet 
IS50 FTIR, Thermo Scientific) in the attenuated total reflectance mode (ATR). The electrodes were 
mounted on an ATR diamond crystal and 64 scans were acquired and averaged to obtain a good 
signal-to-noise ratio. Similarly, the FTIR spectrum of HLM dry coated directly on an ATR diamond 
crystal was obtained for comparison. 
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3.2.5 Microscopic Characterization of the Electrodes 
The surface morphologies of BPG, EPG, GC, and HPG disk electrodes before and after coating 
with a layer of HLM were characterized by scanning electron microscopy (SEM, Model: FEI 
Quanta 600FE). An accelerating voltage of 20 kV was applied. The images were acquired using 
the FEI xT Microscope Control Software.  
3.2.6 Thickness of HLM Film on Different Electrodes  
The dry film thicknesses of adsorbed microsomal films on BPG, EPG, GC, and HPG disk 
electrodes were measured by a spectral reflectance method using a Filmetrics F40 system (Fairport, 
NY, USA). Different locations along the microsomal films were scanned to obtain a range of 
thicknesses representative of the entire surface of each electrode. For each location, the thickness 
was calculated from the reflectance spectrum obtained at a normal incidence in the visible 
wavelength region. The refractive index of HLM was assumed to be 1.54 at 632.8 nm.21 The 
experiment was repeated with three replicate samples of microsomal films for each type of 
electrode.  
3.2.7 XPS Analysis 
X-ray photoelectron spectroscopy (XPS) measurements were performed using the Mg anode of a 
PHI 300 W twin anode X-ray source and the PHI double-pass cylindrical mirror analyzer as the 
detector with pass energy of 100 eV. The instrument comprised a surface analysis system with a 
base pressure of 2 x 10-10 Torr. General survey scans were carried out for polished GC, EPG, BPG, 
and HPG electrodes. Percentage amounts of C and O were calculated for comparison among 
electrodes. 
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3.2.8 Electrochemical Measurements 
A CH instrument 6017E electrochemical analyzer was used for CV experiments. Measurements 
were made in a standard 3-electrode cell consisting of an Ag/AgCl reference electrode (1 M KCl, 
CH Instruments), a Pt-wire counter electrode, and a HLM-coated working electrode disk (BPG, 
EPG, GC, or HPG). A 90% IR compensation was employed before starting the CV scans. For 
anaerobic CV experiments, the cell buffer was purged under high purity nitrogen for 30 min before 
acquiring voltammograms, and a constant nitrogen atmosphere was maintained during 
measurements.  
3.2.9 Electrocatalytic Oxygen Reduction 
Oxygen plays an important role in CYP enzyme-catalyzed reactions by aiding in the formation of 
the reactive CYP-ferryloxy radical cation [+•(CYP-FeIV=O)].3 This oxoform is presumed to be the 
active oxidant of CYPs that can oxygenate a bound drug molecule or other compounds.3,4 Oxygen 
binding to CYPs requires the initial reduction of the heme-cofactor of CYPs by CPR involving an 
in vivo electron donor (e.g., NADPH)4 or it can be driven in vitro via the electrode by an applied 
potential. The HLM catalyzed oxygen reduction was studied in stirred buffer solutions to achieve 
mass transfer by convection,22 which provided better film stability than a rotating disk set-up. 
Defined percentages of oxygen were mixed with nitrogen using two mass flow controllers (Aalborg 
Instruments & Controls Inc., NY, USA) and supplied to the film of HLM on each electrode. The 
percentage O2 was converted to the corresponding concentration using the Henry’s law 
equation.23,24 
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3.2.10 Electrocatalytic Testosterone Hydroxylation and Liquid Chromatography Detection 
of Products 
The electrocatalytic conversion of testosterone to 6β-hydroxytestosterone by the designed 
microsomal films was confirmed by liquid chromatography.16, 17 In brief, the electrodes adsorbed 
with HLM were placed in a stirred, 3-electrode microcell containing 250 µM testosterone in 1 mL 
of potassium phosphate buffer, pH 7.0. The electrolysis was carried out at an applied potential of –
0.6 V vs. Ag/AgCl for 1 h under a constant supply of oxygen. The reaction mixture was analyzed 
by high performance liquid chromatography (HPLC, C-18 Column, Shimadzu LCMS-2010EV). 
The product was identified using standard 6β-hydroxytestosterone (Sigma). For inhibition studies, 
100 µM ketoconazole was added to 250 µM testosterone in pH 7.0 buffer, electrolysis was carried 
out, and the reaction mixture was analyzed by HPLC. A gradient elution involving 
acetonitrile/water solvent mixture was used in HPLC analysis:  10% acetonitrile for 0–10 min 
followed by 10–50% acetonitrile up to 60 min and a constant 50% acetonitrile until 80 min at a 
flow rate of 0.3 mL min–1.  
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3.3 Results and Discussion 
3.3.1 Spectral, Spectroscopic, and Microscopic Characterization of Films of HLM on 
Electrodes  
The formation of a red colored complex in the reaction of HLM with ammonium ferrothiocyanate 
(λmax at 488 nm)20 confirmed the presence of microsomal phospholipids in the adsorbed microsomal 
films (Figure 1A). FTIR characterization of HLM on the various electrodes showed the presence of 
the amide I and amide II bands of microsomal proteins at 1650 and 1542 cm–1, respectively (see 
Figure 1B). Additionally, the fundamental bond stretching frequencies of phospholipids in the 
vibrational region 1300–900 cm–1 were identified by the FTIR characterization.20,25,26  The 
characteristic phospholipid vibrational bands were noted at 1237 (P=O), 1045 (P-O), 990 (P-O-C), 
and 924 cm–1 (C-N of choline group) for microsomal films coated on the electrodes (see Figure 
1B). Similar vibrational bands were also noted for the HLM film coated directly on an FTIR-ATR 
crystal (see Figure 1B), confirming that the electrodes did not induce any notable change in the 
phospholipid structures of adsorbed HLM.  
 
 
 
Figure 1. (A) Representative absorbance spectrum of HLM extracted in chloroform from a 
BPG/HLM electrode and (B) Representative infrared spectrum of HLM adsorbed on an ATR 
diamond crystal (dotted line) or on a BPG electrode (solid line). 
A B 
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The scanning electron micrographs of polished GC, HPG, EPG, and BPG disk electrodes, and those 
adsorbed with a layer of HLM are shown in Figure 2 (A-H). The GC surface is relatively smooth, 
whereas the EPG surface features large surface defects. The BPG surface displayed relatively less 
surface defects,19 and the HPG surface exhibited platelet-like surface defects that differ from pure 
edge and basal planes (see Figure 2 A-D, respectively). All observed surface morphologies of 
polished electrodes are in good agreement with results of prior studies.27-30 Adsorption of a layer of 
HLM on each electrode changed the surface morphology and produced coated film textures, which 
confirmed the formation of microsomal films on the electrodes (see Figures 2 E-H).  
 
Figure 2. SEM images of polished (A) GC, (B) HPG, (C) EPG, and (D) BPG electrodes and these 
electrodes after being coated with a layer of HLM: (E) GC/HLM, (F) HPG/HLM, (G) EPG/HLM, 
and (H) BPG/HLM. 
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 3.3.2 Electrochemical Probing of Microsomal Film Voltammetry 
To drive electrocatalysis of a drug conversion into metabolites, it is necessary that electrons are 
successfully delivered from the electrode to reduce the immobilized liver microsomal proteins. It 
was examined by utilizing cyclic voltammetry to study the direct electron transfer properties of 
designed microsomal films on various carbon electrodes. Figure 3 A shows the background 
subtracted cyclic voltammograms of microsomal films adsorbed on the carbon electrodes in a 
nitrogen atmosphere at pH 7.0. Polished electrodes with an adsorbed phospholipid film (L-α-
phosphatidylchloine) in the absence of microsomal proteins did not show any redox peaks (see 
Figure  3B), and thus confirmed that the direct electron transfer from the electrode to microsomal 
proteins was achieved (see Figure 3A). The peak separation between oxidation and reduction 
potentials with the logarithm of scan rate is shown in Figure 3C for the microsomal films on each 
electrode.  
 
Figure 3. (A) Background subtracted cyclic voltammograms of liver microsomal films physisorbed 
on (a) GC, (b) HPG, (c) EPG, and (d) BPG electrodes at 0.7 V s–1 in anaerobic phosphate buffer, 
nitrogen atmosphere, pH 7.0, 25 oC. (B) The corresponding cyclic voltammograms (a-d) of control 
phosphatidylchloine films adsorbed similarly on the various electrodes. (C) Trumpet plots 
displaying the reduction and oxidation peak potentials of HLM films with logarithm of scan rate 
on (a) GC, (b) HPG, (c) EPG, and (d) BPG electrodes in anaerobic phosphate buffer, pH 7.0, 0.15 
M NaCl, 25 oC. 
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The average formal potential (Eoˈ) of microsomal films was in the range of –0.45 to –0.47 V vs 
Ag/AgCl. The observed Eoˈvalues are in good agreement with prior reports on the formal potential 
of microsomal CPR protein.14,15,17,31,32 On the other hand, purified CYPs (–0.3 to –0.33 V vs 
Ag/AgCl),33 microsomal cyt b5,34 and only CYP-containing microsomes (–0.38 V vs Ag/AgCl)16 
are known to exhibit more positive formal potentials. Furthermore, the anaerobic peak potentials 
of microsomal films in nitrogen did not shift positive upon supplying carbon monoxide (see Figure 
4), which is against the characteristic feature of microsomal CYP enzymes.33 This suggests that the 
observed voltammetric properties of microsomal films are characteristics of oxidoreductases in 
microsomes.13-15  
Figure 4. Background subtracted cyclic 
voltammograms of HPG/HLM films a. in 
N2 and b. after bubbling CO for 15 min, 
scan rate 0.5 V s-1, pH 7.0 buffer, 0.15 M 
NaCl,  25 oC. 
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The peak currents increased linearly with scan rates from 0.005 to 2 Vs–1 for the immobilized 
microsomal films on all four carbon electrodes (see Figure 5). This property confirms the surface-
confined redox voltammetry of HLM. The ratio between the reduction and oxidation peak currents 
was close to unity.  
Figure 5. Peak current vs scan rate for the adsorbed 
microsomal films on (a) GC, (b) HPG, (c) EPG, and (d) 
BPG electrodes in anaerobic phosphate buffer, nitrogen 
atmosphere, pH 7.0, 25 oC.  
 
 
 
Integration of the peak area provided the charge (Q) in coulombs (see Table 1).22 The formal 
potentials of HLM physisorbed on BPG, EPG, GC, and HPG electrodes did not change 
significantly. However, the electroactive amounts (proportional to the measured charge) of 
microsomal films among the surface defective EPG and HPG electrodes were comparable to each 
other, and about 10-times greater than the smooth GC electrode and about 1.5-times greater than 
the moderately defective BPG electrode (see Table 1).  
The positive shifts in formal potentials with decreasing pH suggest the occurrence of proton-
coupled ET processes (involving equal numbers of electrons and protons, see Table 1) in the 
microsomal films on different carbon electrodes. The average shifts in formal potentials per pH 
unit (tested pH conditions: pH 5.5, 6.5, and 7.5) was close to the Nernstian 59 mV pH–1 for the 
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HPG/HLM and EPG/HLM films and higher than 59 mV for the GC/HLM and BPG/HLM films 
(see Table 1)14. The peak width at half maximum (PWHM) was in the range of 63-82 mV for all 
microsomal films (see Table 1). This range is between the ideal 90.6 and 45.3 mV for one electron 
and two electron processes, respectively.22  
Table 1. Electrochemical parameters of liver microsomal films adsorbed on different carbon 
electrode materials under nitrogen atmosphere. 
Film Type 
Eoˈ/ V vs 
Ag/AgCl 
Q / nC 
PWHM / 
mV 
ΔEo' / pH 
mV 
ks (s–1) 
GC/HLM 0.45 (± 0.01) 33 ± 2 63 ± 4 72 ± 6 91 ± 11 
HPG/HLM 0. 45 (± 0.005) 330 ± 58 68 ± 2 64 ± 5 61 ± 4 
EPG/HLM 0.45 (± 0.01) 347 ± 20 82 ± 2 57 ± 6 36 ± 4 
BPG/HLM 0.47 (± 0.005) 232 ± 20 74 ± 4 75 ± 8 29 ± 5 
 
Prior studies showed that FAD can accept up to two electrons from NADPH, whereas FMN acts as 
a one electron carrier to reduce CYPs in the biocatalytic pathway.3,4,35 The observed lower PWHM 
values of liver microsomal films are similar to that reported for rat liver microsomes in layer-by-
layer films with polyions (~ –0.45 V vs Ag/AgCl, pH 7.0, PWHM 70 ± 8 mV).14 For purified 
human CPR in surfactant films (~ – 0.47 V vs Ag/AgCl, pH 8.0) that exhibited a PWHM of 70 mV, 
a multi-electron transfer process was inferred.31  Based on our results and the reported literature, 
the possibility for a one electron process or a mixed one and two electron transfer processes taking 
place in the direct electrochemistry of the designed microsomal films can be suggested. Overall, 
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the examined electrochemical properties infer the non-ideal surface voltammetry of liver 
microsomal proteins. 
3.3.4 Electrode-dependent Electron Transfer Kinetics 
From the increase in peak separation with scan rates (see Figure 3C) that was subtracted for the 
non-zero constant peak separation at low scan rates (≤ 100 mVs–1), similar to other reported 
studies,33,36-38  the direct ET rate constants (ks, s–1)39 of microsomal films on the BPG, EPG, GC, 
and HPG disk electrodes were determined (see Table 1). The resulting fit of peak separation with 
the Butler-Volmer surface voltammetry showed good agreement (Figure 6).33,38,39  
Figure 6. Experimental peak 
separation (corrected for the non-
kinetic constant residual peak at low 
scan rates) with increasing scan rates 
for HLM films adsorbed on (a) GC   
(), (b) HPG (), (c) EPG (▲), and 
(d) BPG (♦) electrodes and the 
theoretical lines obtained by Butler-
Volmer surface-voltammetry for the 
experimentally determined average 
rate constants (ks, Table 1) and α = 
0.5.  
 
 
The direct ET rate of the microsomal film on the smooth GC electrode was 2.5–3.0 times greater 
than that of the microsomal films on the BPG and EPG electrodes and 1.5-times greater than that 
of the microsomal film on the HPG electrode (see Table 1). The magnitudes of electroactive 
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coverage and ET rates suggest that electrode roughness and surface defects favor enhanced amounts 
of electroactive microsomal proteins (e.g., HPG and EPG), while flat and surface defect-free GC 
surface seems to allow HLM molecules to orient in a uniform manner with a net fast ET rate (see 
Figure 2, SEM images). Figure 3C shows that the greater peak separation of microsomal films in 
the respective electrodes with increasing scan rates correlates inversely with the determined rates 
of direct ET (see Table 1), as per the Butler-Volmer surface voltammetry.39  
3.3.5 Film Thickness and Electrochemical Kinetics  
Spectral reflectance measurements illustrated that the nominal range of dry film thicknesses of 
microsomal films on the defective EPG and HPG electrodes was greater than that of the smooth 
GC and less defective BPG electrodes as presented in Table 2. The upper limits of dry film 
thicknesses of HLM among electrodes qualitatively correlated with the measured extent of 
electroactive amounts (see Table 1). In contrast, significant differences were observed in the 
kinetics of ET and film stability among the microsomal films on the different electrodes. For 
example, GC/HLM and BPG/HLM films of similar thicknesses displayed the highest and lowest 
direct ET rates, respectively. A similar feature is also reflected in the ks values among the 
EPG/HLM and HPG/HLM electrodes (see Tables 1 and 2). 
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Table 2. Thickness data of the immobilized microsomal films on different electrodes. 
 
 
 
 
 
The absence of correlation between film thickness and ET kinetics suggests the need to consider 
electrode factors such as surface defects, roughness, geometry, and chemical groups that can 
influence the secondary interactions between the electrode and the phospholipid membranes of 
HLM (see Figure 1 and further discussion below on XPS analysis). These factors in turn can alter 
the orientations of membrane-bound oxidoreductases and metabolic enzymes with respect to 
electrode. Hence, the pathway of ET between electrode and membrane-bound microsomal proteins 
appears to be the underlying factor in controlling electrochemical kinetics. 
3.3.6 Surface Properties and Connection to Electrochemical Rates 
The surface characteristics of polished electrodes were determined by XPS analysis as shown in 
Figure 7. Results indicate that the GC surface contains the highest oxygen content and the BPG 
surface has the lowest oxygen content and the reverse was observed with regard to carbon levels. 
EPG and HPG surfaces consist of intermediate oxygen levels, and carbon content close to the BPG 
Film Type 
Dry Film 
Thickness (µm) 
GC/HLM 0.3–1.3 
HPG/HLM 5.0–10.0 
EPG/HLM 2.0–8.5 
BPG/HLM 0.2–3.0 
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(see Table 3). The determined percentage values of C and O composition are in agreement with the 
reported literature on polished graphite and glassy carbon surfaces.40-43 
 
 
 
 
  
Figure 7. XPS spectra of polished electrode surfaces. 
Surface oxygen density can be related to the extent of polarity and the surface carbon levels to the 
extent of hydrophobicity. The flat/smooth surface (see Figures 2A) of GC is ascribed to enable 
uniform HLM layer arrangement (with homogeneous protein orientation) and highly polar nature 
(see Table 3) is attributed to favor faster charge transfer kinetics in a relatively thinner film of HLM 
on GC over other electrodes. On the other hand, less polar nature of BPG with irregular surface 
appears to have varying interactions with the phospholipid membranes of HLM and cause mixed 
orientations of microsomal proteins in film, resulting in slower ET rates. HPG and EPG electrodes 
with intermediate levels of oxygen functionalities with respect to BPG and GC, and with extensive 
surface defects showed ET rate constants falling between that of BPG and GC.  
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Table 3. Carbon and oxygen levels of four carbon electrodes. 
 
 
 
 
 
 
 
Taken together, this study found that surface oxygen density of a carbon electrode influences charge 
transports in the phospholipid membranes of immobilized HLM. It is important to note that the 
determined electron transfer rate constants determined are representative of the whole film of HLM 
on a given electrode and are not controlled by one specific electrode property due to the complexity 
of interactions between an electrode and HLM as against a simple purified protein system.   
 
 
Electrode Carbon Oxygen 
GC 77% 23% 
HPG 91% 9% 
EPG 89% 11% 
BPG 94% 6% 
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3.3.7 Electroactive Microsomal Film Stability on Electrodes 
The electroactive stability of microsomal films on BPG, EPG, GC, and HPG electrodes was 
monitored by cycling the potential continuously between 0 and –0.6 V vs Ag/AgCl for 200 cycles 
(scan rate 0.1 Vs–1) in anaerobic pH 7.0 buffer. The GC/HLM film retained ~30% of initial current, 
the HPG/HLM and EPG/HLM films retained about 85% of the initial currents, and the BPG/HLM 
film retained about ~50% of the initial current. This level of electroactive HLM stability after 200 
cycles on the HPG and EPG electrodes is likely satisfactory for electrocatalytic and biosensing 
applications.  
3.3.8 Electrochemical O2 Binding Kinetics to HLM 
Oxygen is required in CYP-catalyzed monooxygenase activity to form the active CYP-heme 
oxidant, which can subsequently transfer the reactive oxygen to oxidize a bound substrate.4,18 For 
oxygen to bind CYPs, the FeIII-heme of CYP needs to be reduced first to the FeII-heme-CYP form 
(a one e– reduction). Figure 8 (see solid curve in red) shows the catalytic cyclic voltammograms of 
oxygen reduction currents by microsomal films on the various carbon electrodes. The relative 
magnitudes of oxygen reduction currents among the designed microsomal films were in the 
following order: HPG/HLM ≈ EPG/HLM > GC/HLM > BPG/HLM.  
The cyclic voltammograms of polished bare electrodes or those adsorbed with a phospholipid layer 
in the absence of immobilized microsomes did not show the characteristic enzyme-mediated 
electrocatalytic oxygen reduction (see Figure 8, broken curves), but rather displayed small 
reduction currents at more negative onset potentials that were due to direct oxygen reduction at 
carbon electrodes. This result confirms the specific role of microsomal heme proteins in catalyzing 
oxygen reduction that appears to be facilitated by electron donation from electrode-reduced CPR 
molecules (see Figure 3A). It is also possible that microsomal Cyt b5-heme may undergo reduction 
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by the electrode-reduced CPR. However, this reduction process in the presence of vesicles (as the 
case for microsomes) has been shown to be slow and less favorable.44  
Figure 8. Cyclic voltammograms of 
microsomal films (red), 
phospholipid films (blue) and bare 
electrodes (green) of (A) GC, (B) 
HPG, (C) EPG and (D) BPG 
electrodes in 0.9 mM oxygen 
concentration. Experimental 
conditions: stirred pH 7.0 phosphate 
buffer, 0.15 M NaCl, 25 oC, scan rate 
0.3 V s-1.  
 
 
 
Oxygen reduction currents by microsomal proteins on electrodes were analyzed by Lineweaver-
Burk kinetics (see Figure 9) to obtain the apparent Michaelis-Menten affinity constant (KM) of each 
microsomal film. Estimated apparent KM values among four electrodes were in the range of 0.5-
1.0 mM, which is not appreciably different. A possible reason could be the observed reductase-like 
direct electrochemistry of HLM (see Figure 3A), and as a result indirect oxygen binding to 
reductase-reduced heme proteins in HLM films is not directly influenced by the type of electrode 
used. 
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Figure 9. Lineweaver-Burk plot for 
oxygen reduction currents versus oxygen 
concentration for (a) GC/HLM, (b) 
HPG/HLM, (c) EPG/HLM and (d) 
BPG/HLM electrodes. Experimental 
conditions: stirred phosphate buffer pH 
7.0, scan rate 0.3 V s-1, 25 oC. 
 
 
 
3.3.9 Electrocatalytic Testosterone Hydroxylation and CYP-specific Inhibition 
The biocatalytic activity of liver microsomal films was inverstigated by monitoring the conversion 
of testosterone to 6β-hydroxytestosterone via bulk electrolysis at an applied constant potential of –
0.6 V vs Ag/AgCl followed by HPLC detection of the product. Among several CYP enzymes, the 
CYP 2C9, 2C19, and 3A4 present in HLM have been shown to play roles in catalyzing the 
testosterone hydroxylation.46 For the electrolysis study, the catalytically superior and relatively 
more stable HPG/HLM film were chosen as an optimal electrode system identified. After 
electrolysis, the reaction mixture was analyzed by HPLC, and the hydroxylation product was 
identified using the standard 6β-hydroxytestosterone (see Figures 10a and 11 B-a).  
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To determine whether the testosterone hydroxylation by the HPG/HLM film was catalyzed by 
CYPs, the reaction was performed in the presence of ketoconazole, a potent inhibitor of CYP 
activity towards testosterone hydroxylation.16 Figure 10 b shows that ketoconazole inhibited the 
CYP-catalyzed formation of 6β-hydroxytestosterone. The observed biocatalytic property indicates 
that HLM directly adsorbed on HPG can facilitate electron transfer from electrode to CPR to CYPs 
and retain the bioactivity of bound CYPs. Moreover, it was confirmed that polished bare HPG 
electrode in the absence of HLM did not catalyze the testosterone hydroxylation (see Figure 11 A). 
Figure 11 B provides the chromatograms of the 6β-hydroxytestosterone standard and ketoconazole 
inhibitor. 
 
Figure 10. HPLC chromatograms of reaction mixture after 1 h of electrolysis of HPG/HLM 
electrodes at –0.6 V vs Ag/AgCl under a constant oxygen supply at 25 oC, pH 7.0: (a) 250 µM 
testosterone; (b) 250 µM testosterone + 100 µM  ketoconazole.  
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Figure 11. (A) HPLC chromatograms of 250 µM testosterone after 1 h of electrolysis of polished 
bare HPG electrodes at –0.6 V vs Ag/AgCl under a constant oxygen supply at 25 oC, pH 7.0 and 
(B) HPLC chromatograms of (a) 250 µM 6β-hydroxytestosterone standard and (b) 100 µM  
ketoconazole inhibitor. 
 
A 
B 
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3.4 Conclusions 
The results presented demonstrate the feasibility of designing a one-step, rapid microsomal 
bioreactor on optimal HPG or EPG electrodes for biocatalytic applications. Film thickness of HLM, 
stability, and electroactive protein amounts are controlled by the extent of electrode surface defects, 
while rate of ET is controlled by the combined effects of surface oxygen functionalities and surface 
flatness of electrodes. Considering the importance of human liver microsomes in pharmaceutical 
drug development and toxicology fields, the presented method to simplify the microsomal 
bioelectrode design is suggested to be useful for inexpensive drug metabolism and inhibition 
assays. It is envisioned that the new findings of this study will have notable significance in the 
design of modern one-step liver microsomal electrodes for rapid electrochemical biosensing and 
biocatalytic applications. 
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CHAPTER 4 
 
SINGLE DROP ELECTROANALYSIS AND INTERFACIAL INTERACTIONS: 
SENSITIVITY VERSUS LIMIT OF DETECTION 
 
4.1 Introduction 
Chemical reactions in bulk solutions have been studied extensively, and researchers have started 
exploring reactions using ultra-small volumes due to advantages such as faster reaction kinetics, 
enhanced analytical sensitivity, and small sample requirements.1-3 Superior biochemical 
characteristics of droplets are due to enhanced mixing and mass transfer and the ability to function 
as small reactors.4-5 Investigation of such properties via quantitative and qualitative analysis of the 
contents of droplets is only possible with sophisticated analytical techniques, including molecular 
spectroscopy, mass spectrometry, electrophoresis, and electrochemistry.6  
Among the various analytical techniques available, electrochemical detection of analyte droplets is 
favored due to its simplicity, cost-effectiveness, and the ability to modify the electrode surface to 
obtain good sensitivity.7-8 Interfacial electrochemistry of droplets placed on electrodes and 
fundamental insights based on mass and ion transfer mechanisms have been reported.9  Recently, 
Oliveira et al. showed that a single drop electrochemical system consisting of two liquid phases of 
water and oil can diminish charge transfer resistance in the detection of 4-nitrophenol in oil.10 Using 
a single drop of redox active hexachloroiridate, changes in the heterogeneous electron     
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transfer rates with respect to number of layers of graphene and microscopic defects on the graphene 
surface (edge/basal planes) were electrochemically investigated.11 
Heavy metals,12 polycyclic aromatic hydrocarbons,13  microorganisms, radioactive agents, and 
many other environmental pollutants14  can be monitored via single drop electrochemical analysis. 
Blood glucose analysis is a remarkable point-of-care biomedical application of single drop 
electrochemical biosensors.15-17  Chen et. al. developed a disposable screen printed electrode (SPE) 
approach for detection of uric acid in droplets of whole blood.18  Thus, biologically and chemically 
relevant analytes have been detected in ultra-micro volumes. 
In this study, the electroanalytical measurements of four compounds in single droplets were 
performed on carboxylated multiwalled carbon nanotubes (MWCNT-COOH) modified SPEs and 
their presence and concentration were detected using cyclic voltammetry. Acetaminophen is a pain 
reliever and fever reducing drug; NADH is a co-enzyme and a dietary supplement; ascorbic acid is 
an antioxidant and also used as a dietary supplement; and nicotine is a tobacco smoke carcinogen 
and present in anti-smoking pharmaceuticals. The focus of this study was to evaluate the detection 
sensitivity and limit of detection (LOD) of single drop assays relative to molecular sizes of anlaytes, 
and polar and nonpolar interfacial interactions of analytes with the MWCNT- COOH surface. To 
our knowledge, this study is the first to describe single drop electroanalysis for the selected 
compounds with insights into interfacial interactions controlling sensitivity and LOD. Detailed 
electron transfer, mass transport, and electrochemical kinetics were investigated in a separate study. 
Results of this study convey the importance of electroanalytical methods in measuring low levels 
of analytes and the significance of droplet-based biosensors utilizing desired chemically or 
biologically functionalized  SPEs. SPEs were chosen because of their user-friendly design, 
miniature size, portability, low cost, and disposability and because they lack interference arising 
from surface contamination and cleaning protocols between experiments.19-20 Figure 1A illustrates 
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the schematic of SPEs for single drop analysis of analytes based on electrochemical methods. 
Figure 1B shows the structures of measured analytes in this study as single drops. 
 
 
Figure 1. (A) Schematic representation of single droplet analysis using SPE made of a carbon 
counter electrode (CE), an MWCNT-COOH coated working electrode (WE), and a silver pseudo-
reference electrode (RE). (B) a-d. Chemical structures of measured analytes as single drops. a. 
acetaminophen, b. nicotine, c. ascorbic acid, and d. NADH.  
 
4.2 Experimental 
4.2.1 Materials  
SPEs (110 CNT, dimensions: length 33 mm; width 10 mm; height 0.5 mm) were purchased from 
Dropsens Ltd. [Llanera (Asturias) Spain]. The SPE electrode geometric area was 0.16 cm2, and it 
was modified with MWCNT-COOH. The counter electrode was made of carbon and the pseudo-
reference electrode was made up of silver. L-Nicotine was purchased from ACROS Organics and 
all other analytical grade chemicals, including acetaminophen, L-ascorbic acid, and NADH (β-
Nicotinamide adenine dinucleotide, reduced disodium salt hydrate), were purchased from Sigma. 
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Acetaminophen, ascorbic acid, and NADH  tablets, and nicotine gum were purchased from a local 
pharmacy.  
4.2.2. Cyclic Voltammetric Measurements 
A CH instrument 6017E electrochemical analyzer was used for cyclic voltammetry experiments 
under ambient atmosphere. Different concentrations of the four analytes prepared in pH 7.0 
phosphate buffer were placed as 50 µL droplets on SPEs, and voltammograms were obtained.  
4.2.3 Sample Preparation  
Acetaminophen (2 of 500 mg), ascorbic acid (1 of 1000 mg), and NADH (8 of 5 mg) tablets were 
finely powdered and transferred separately into 250 mL conical flasks containing 100 mL of  pH 
7.0 phosphate buffer. Then the contents of flasks were sonicated for 30 min, and the mixtures were 
filtrated through Whatmann filter papers to remove insoluble materials. Filtrates were used for 
voltammetric analysis. The nicotine containing chewing gums (2 of 4 mg) were cut and dissolved 
in 20 mL of hexane. The mixture was then filtered and extracted with 100 mL, pH 7.0 phosphate 
buffer. The buffer extract was used for voltammetric analysis.21 Appropriate sample dilutions were 
made to fit in the voltammeric calibration plots and estimate the amounts in the real samples. 
4.3 Results and Discussion 
4.3.1 Electrochemical Behavior of Analytes 
The analytes were placed as a single drop (50 µL volume) on separate MWCNT-COOH SPEs, and 
electrochemical signals were measured by cyclic voltammetry. Figure 2 shows the background 
cyclic voltammograms (CVs) for buffer droplets on the SPE electrodes (dotted lines) and that of 
100 µM analyte droplets (bold lines). A small sharp spike (0 - 0.1 V range) was observed for bare 
SPEs in buffer droplets, but the spike did not interfere with the identification of analyte peaks.  
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Figure 2. CVs of 100 µM droplets (50 
µL volume) of (A) acetaminophen, (B) 
nicotine, (C) ascorbic acid, and (D) 
NADH placed on MWCNT-COOH 
SPEs at 25 oC, scan rate 25 mV s–1 
(solid lines). Dashed lines are the CVs 
of a buffer drop with no added analyte. 
 
 
 
 
Figure 3 represents the CVs of analyte droplets with increasing scan rates (at 1 mM analyte 
concentration). A linear relationship between oxidation peak currents and the square root of scan 
rates was observed for all four analytes (see insets in Figure 3). This indicated the diffusion-
controlled electrochemical process of analytes in droplets of 50 µL volume.22   
Figure 3 also illustrates the differences in the CV peak shapes of each analyte. For example, 
acetaminophen CVs suggested a quasi-reversible process (significant peak separation between 
oxidation and reduction peaks with increase in scan rate), and nicotine, ascorbic acid and NADH 
displayed the feature of almost irreversible redox process. These variations in peak shapes are 
indicative of differences in the kinetics of direct electron transfer and mass transport of analyte 
molecules at the interface of the droplet and MWCNT-COOH SPE.22    
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Figure 3. Scan rate dependent CVs of 1 
mM droplets (50 µL volume) of (A) 
acetaminophen, (B) nicotine, (C) ascorbic 
acid, and (D) NADH placed on MWCNT-
COOH SPEs. (scan rates inner to outer : 5 
to 1000 mV s–1). Insets show the plots of 
peak current vs square root of scan rate. 
 
 
 
 
Figures 4A-D show the CVs for various concentrations of acetaminophen, nicotine, ascorbic acid, 
and NADH [(i) is for lower concentration range and (ii) is for higher concentration range of analyte 
droplets]. 
 
Figure 4. CVs of 50 µL droplets of varying concentrations of analytes placed on MWCNT-COOH 
SPEs at 25 oC, scan rate 25 mV s–1: (A) acetaminophen, (B) nicotine (inset shows the enlarged view 
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of  voltammograms), (C) ascorbic acid, and (D) NADH: (i) CVs at lower concentration range and 
(ii) CVs at higher concentration range. 
Figure 5A shows the increase in oxidation peak currents with increasing concentration of each 
analyte. The sensitivity of the method from the slopes of this plot was estimated. The LOD of each 
analyte was calculated to be 3Sb/m, where Sb is the standard deviation of the blank signal and m is 
the slope of the calibration plot (see Table 1).23-24 The observed wide dynamic range of detection 
(from the LOD to 1 mM) is comparable to or better than that of many reported carbon-based SPE 
sensors for similar analytes.7, 25-29  
Figure 5.  (A) Oxidation peak currents versus concentration of a single drop of analyte placed on 
MWCNT-COOH SPEs at 25 oC and measured by cyclic voltammetry at a scan rate of 25 mV s–1. 
(B) Effect of varying concentration of analytes on the oxidation peak potential. 
 
The oxidation peak potential of each analyte shifted to more positive values with increasing 
concentration (see Figure 5B). The peak shifts were more prominent for ascorbic acid and NADH 
compared to nictotine acetaminophen. This observation suggests greater overpotential 
requirements at higher concentrations of  relatively polar compounds due to possible charge 
repulsions with the surface (related to energetics). Once the required overpotential barrier is 
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overcome, analytical detection features from interfacial charge transfer can be achieved (i.e., 
current signals).30 
The differences in the observed LODs and sensitivity among the four analytes can be explained by 
the nature of interfacial secondary interactions of analytes with the MWCNT-COOH-modified SPE 
surface. A MWCNT is made of concentric cylindrical layers of graphene. MWCNT-COOH 
contains both polar –COOH groups and nonpolar sp2 carbons of MWCNT. The sidewall basal 
planes of MWCNT can undergo pi-pi stacking as well as nonpolar interactions with pi-bonds and 
nonpolar groups of analytes.31  The edge planes and defective sites of MWCNT are mostly polar. 
The -COOH groups of MWCNT offer electrostatic and hydrogen bond interactions with the polar 
groups of analytes.  
The data showed that higher sensitivity does not always correlate with lower LOD in 
electroanalysis (Table 1). In this study, the decreasing order of detection sensitivity was 
acetaminophen > nicotine > ascorbic acid > NADH (see Figure 5A). The highest sensitivity 
observed for acetaminophen can be explained by its combined pi-pi and nonpolar interactions with 
MWCNT along with hydrogen bonding and electrostatic interactions with surface –COOH groups 
(via –OH and NH groups) (see Figure 6). Ascorbic acid is relatively more polar than acetaminophen 
and thus can interact predominantly via dipole-dipole and hydrogen bonding interactions with the 
MWCNT-COOH surface. This major polar interaction (i.e., less nonpolar) might be the reason for 
this anlayte’s lower sensitivity compared to acetaminophen. Similarly, although NADH is polar, 
the relatively larger size of this compound compared to ascorbic acid can cause sterically hindered 
interaction with the electrode and thus explains its low detection sensitivity on the MWCNT-COOH 
surface. 
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Table 1. Electroanalytical measurements of single drops of acetaminophen, nicotine, ascorbic acid, 
and NADH. 
 
 
 
 
 
 
 
 
Nicotine is the least polar of the four compounds and it has predominantly nonpolar (e.g., 
dispersion, pi-pi) interactions, which further supports the influence of nonpolar interactions in 
providing better sensitivity than polar ascorbic acid and NADH molecules.  
 
 
 
 
 
Analyte Oxidation Peak Potential / mV 
(at 100  μM) 
LOD (μM) Sensitivity 
(nA μM
-1) 
Acetaminophen 327 ± 7 0.13 36 
Nicotine 1006 ± 4 4.8 25 
Ascorbic acid 38 ± 3 0.83 18 
NADH 247 ± 27 1.7 9 
  
65 
 
 
 
Figure 6. Possible interfacial interactions of analytes with the MWCNT surface and –COOH 
groups; these interactions may explain the observed variations in sensitivity and LODs of the 
measured analytes. 
       
 
The following trend of increasing magnitudes of LODs was observed: acetaminophen < ascorbic 
acid < NADH < nicotine. This observation suggests that polar compounds (acetaminophen, 
ascorbic acid, and NADH) favor better charge transport at the interface of an analyte droplet and 
the MWCNT-COOH SPE surface than moderate polar/nonpolar compounds (e.g., nicotine). The 
lowest LOD of acetaminophen is attributed to the synergistic combination of polar and nonpolar 
interactions with the MWCNT surface and –COOH functional groups as described above.  
Taken together, the results suggest that the detection sensitivity of a redox analyte is controlled by 
the extent of predominant nonpolar interactions of the analyte with the MWCNT-COOH SPE 
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sensor surface. However, LOD is controlled by the extent of charge transfer occurring at the 
interface of analyte molecules and the electrode and is favored by polar interfacial interactions. 
Thus, higher sensitivity does not always have to correlate with lower detection limits in an 
electroanalytical method.   
4.3.2 Application to Commercial Pharmaceuticals 
The practical application of the SPEs for single drop electroanalysis of  acetaminophen, nicotine, 
ascorbic acid, and NADH was validated using real pharmaceutical samples. Sample preparation is 
described under Experimental. The results are summarized in Table 2. 
Table 2. Determination of acetaminophen, nicotine, ascorbic acid, and NADH in commercially 
available pharmaceuticals. 
Sample Label amount (mg) Determined (mg) Recovery (%) 
Acetaminophen tablet 500 489 ± 10 97.8 
Nicotine chewing gum 4 3.7 ± 0.1 92.2 
Ascorbic acid tablet 1000 985 ± 20 98.5 
NADH tablet 5 5.0 ± 0.2 99.4 
 
Excellent recovery percentages (> 97%) were obtained in the estimation of acetaminophen, 
ascorbic acid, and NADH in commerically available tablets. The relatively lower percentage 
recovery of nicotine in chewing gum (~ 92%) is attributed to the extraction efficiency of the 
procedure followed rather than the detection aspect.  
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4.4 Conclusions 
In summary, a single drop analysis of four pharmaceutically and biologically relevant compounds 
was described using MWCNT-COOH-modified SPEs. The favorable large surface area and 
multiple interactions offered by the electrode surface provided highly sensitive detection of 
analytes with a wide dynamic range, and interfacial charge transport facilitated by polar interactions 
offered lower detection limits. Above droplet electroanalytical method and the fundamental 
insights regarding the molecular interactions with the sensor surface should allow design of sensors 
with high sensitivity and low detection limits via appropriate control of surface properties to induce 
desired interfacial interactions based on analyte structures confined in a droplet. Successful 
demonstration on real samples implies negligible interferences from the matrix and applicability of 
the method for pharmaceutical quality assurance (QA) purposes. 
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CHAPTER 5 
 
 
EDGE-TO-EDGE INTERACTION BETWEEN CARBON NANOTUBE-PYRENE 
COMPLEXES AND ELECTRODES FOR BIOSENSING AND ELECTROCATALYTIC 
APPLICATIONS 
 
5.1 Introduction 
Carbon nanotube-mediated enhanced biocatalytic reactions of enzymes is an emerging research 
area. Applications of CNTs in the globally important areas of biocatalysis, biodevices, biosensing, 
and sustainable energy have been detailed in the literature.1-3  In this study, w the π-π stacked 
nanotube-pyrene-based surface chemistry that allows covalent immobilization of enzyme catalysts 
was focused to study relevant direct electrochemical and biocatalytic properties.4 Pyrolytic graphite 
material consists of basal (parallel to the surface) and edge planes (perpendicular to the surface). 
Dai et al. reported that the basal plane of sidewalls of CNTs could undergo π-π interaction with 
functionalized pyrene compounds, which would allow facile covalent protein immobilization.5 
Compton et al. unraveled the contribution of CNT edge planes to the electrocatalytic properties of 
CNTs.6 They also illustrated the greater electroactivity of edge plane electrodes over basal plane 
electrodes for a dissolved redox species in solution. 
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In another study, Lisdat et al. investigated the effects of different aromatic compounds stacked with 
CNT-modified electrodes on the oxygen reduction efficiency of immobilized bilirubin oxidase 
enzyme. Krishnan and Armstrong developed a membraneless hydrogen fuel cell with enhanced 
power output and stability by covalently immobilizing E. coli hydrogenase-1 as the anode catalyst 
and bilirubin oxidase as the cathode catalyst on CNT-pyrenebutyric acid (CNT/Py)-modified 
electrodes.8 Katz et al. designed an implantable glucose biofuel cell that utilized CNT-pyrene 
surface chemistry.9 Direct and efficient reduction of oxygen by laccase immobilized on different 
pyrene compounds-modified CNT electrodes has also been shown.10,11 These studies show that 
nanotube-pyrene-based electrode surface modification for biocatalytic applications is receiving 
immense attention at present.  
Our group has previously demonstrated the differential immobilization of a heme protein via Lys 
or Glu residues onto different pyrene derivatives bound to CNTs on the surface of high purity 
graphite (HPG) electrodes.4 Since an HPG surface consists of a mixture of basal and edge planes 
to varying extents, the selective interaction of CNT with either basal plane or edge plane in affecting 
the pyrene compound stacking and electrocatalytic properties of immobilized redox enzyme is not 
easily understood. It can be proposed that the understanding this fundamental feature is crucial for 
designing efficient electrochemical enzyme biosensors and bioreactors. 
Therefore, in this study, the interaction of purely basal plane (BP) or purely edge plane (EP) 
pyrolytic graphite electrodes with multi-walled carbon nanotubes (MWNT), π-π stacked with 
pyrenyl compounds in influencing the electrocatalytic properties of immobilized myoglobin (Mb), 
was demonstrated using as a redox protein model. For comparison, two non-graphitic electrodes 
(with no EP or BP surface) including glassy carbon (GC) and gold (Au) electrodes were chosen. 
The MWNT/Py modification was performed on each electrode surface, and this step was followed 
by the covalent immobilization of Mb (denoted as MWNT/Py-Mb). The procedure to covalently 
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attach myoglobin to obtain MWNT/Py-Mb films is similar to that described in our gorup’s prior 
report.4 
In this study, the results of electrocatalytic currents, electroactive enzyme coverage, and 
spectroscopic studies are compared to understand the influences of the underlying edge versus basal 
plane surface on MWNT/Py modification and subsequent peroxidase activity of the attached Mb 
film. The electrochemical and electrocatalytic peroxide reduction properties of immobilized Mb on 
the designed various electrode materials were investigated by cyclic and rotating disk voltammetry 
(RDV) methods, respectively. 
5.2 Experimental 
5.2.1 Chemicals and Materials 
Disk electrodes made of purely EP or purely BP (Momentive Performance Materials Ltd.), and 
non-graphitic Au and GC electrodes (CH Instruments) were used in this study (geometric area of 
each electrode was 0.2 cm2). MWNT (outer diameter 10–15 nm, inner diameter 2–6 nm, length 
0.1–10 μm), equine heart myoglobin (Mb, ≥ 90%, SDS-PAGE), dimethyl formamide (DMF), 1-
pyrenebutyric acid (Py), t-Butyl hydroperoxide (t-BuOOH),  1-ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride, and N-hydroxysuccinimide were purchased 
from Sigma (Milwaukee, USA). All other chemicals were analytical grade.  
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5.2.2 Preparation of Protein Films on Various Electrodes Modified with MWNT/Py Units 
The procedure to covalently attach myoglobin to MWNT/Py-modified electrodes to obtain 
MWNT/Py-Mb films was similar to that described in our group’s prior reports.2,8 Briefly, 15 µL of 
1 mg mL–1 MWNT in DMF were dry coated on electrodes and π-π stacked with Py (10 mM in 
DMF) molecules. The Mb surface lysine residues (PDB: 2FRF) were covalently attached to the –
COOH groups of the MWNT/Py surface of various electrodes by amine-carboxylic acid coupling 
chemistry (denoted as electrode/MWNT/Py-Mb, where electrode = EP, BP, GC, or Au). The 
electrochemical and electrocatalytic peroxide reduction properties of immobilized Mb on the 
designed electrode materials were investigated by cyclic voltammetry and rotating disk 
voltammetry (RDV) methods, respectively.  
5.2.3 Instrumentation 
Electrochemical measurements were performed using a CH instrument (Model: CHI 6017E, Texas, 
USA). RDV was performed to study the catalytic reduction rate of t-BuOOH at a rotation rate of 
1000 rpm (EcoChemie Autolab rotator supplied with a motor controller, Metrohm Inc.).  A three-
electrode electrochemical cell equipped with an Ag/AgCl reference (3 M KCl), a Pt-wire counter 
electrode, and MWNT/Py-Mb films on the various working electrodes were used. Fluorescence 
emission spectra of Py solutions were obtained using a Varian Cary eclipse fluorescence 
spectrophotometer. The excitation and emission slit widths were set at 5 nm. The excitation 
wavelength was set at 284 nm and emission was monitored at 377 nm. The X-ray photoelectron 
spectroscopy (XPS) analyses were performed using the Mg anode of a PHI 300 W twin anode X-
ray source and the PHI double-pass cylindrical mirror analyzer as the detector with a pass energy 
of 100 eV. The instrument was equipped with a surface analysis system with a base pressure of 2 
x 10–10 Torr. General survey scans were carried out for the EP/MWNT/Py-Mb and BP/MWNT/Py-
  
74 
 
 
Mb electrodes to qualitatively assess how the edge and basal plane effects on MWNT/Py 
modification and influence the surface density of immobilized Mb molecules. 
5.3 Results and Discussion 
Figure 1 represents the background subtracted anaerobic (in nitrogen) cyclic voltammograms (CVs) 
of the designed Mb films on EP, BP, GC, and Au electrodes. The observed reversible CVs confirm 
the direct electronic communication between the modified electrodes and the Mb-heme redox 
center.12 
Figure 1. Background subtracted cyclic 
voltammograms of MWNT/Py-Mb films on a. 
EP, b. BP, c. GC, and d. Au electrodes at 25 oC 
in anaerobic nitrogen purged phosphate buffer 
containing 0.15 M NaCl (pH 7.0), scan rate 0.5 
Vs–1. 
 
 
 
 
Figure 2 shows the tert-Butyl hydrogenperoxide (t-BuOOH) reduction currents catalyzed by the 
covalent Mb films on various electrode materials modified with MWNT/Py units (see curves a-d). 
These catalytic currents were subtracted for the small background currents (due to direct oxygen 
reduction) from the respective MWNT/Py films on each electrode with no attached Mb (see Figure 
2, e-h).  
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Figure 2. Peroxide reduction currents for 
modified MWNT/Py-Mb films on a. EP, b. 
BP, c. GC, and d. Au electrodes at 2.0 mM 
t-BuOOH. The small background currents 
from MWNT/Py films in the absence of 
immobilized Mb on each electrode are also 
shown (curves e-h). Experimental 
conditions: anaerobic pH 7.0 phosphate 
buffer, 0.15 M NaCl, 25 oC, scan rate 0.1 V 
s–1, rotation rate 1000 rpm. 
 
 
 
 
The Tafel analysis of the catalytic voltammograms yielded similar slope values for all Mb films on 
MWNT/Py-modified electrodes (see Figure 3). This indicates that similar peroxide reduction 
mechanism is followed by the designed Mb films.13  The decrease in Tafel slope values at low over-
potentials can be attributed to the presence of adsorbed peroxide molecules on the modified protein 
electrode surfaces to rapidly undergo reduction (see Figure 3).14 
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Figure 3. Tafel plots for peroxide reduction 
by MWNT/Py-Mb films on a. EP, b. BP, c. 
GC, and d. Au electrodes for the catalytic 
voltammograms shown in Figure 2 
 
 
 
 
The average reduction current densities among the BP/MWNT/Py-Mb and non-graphitic 
GC/MWNT/Py-Mb and Au/MWNT/Py-Mb electrodes were comparable to each other. In  contrast, 
the EP/MWNT/Py-Mb electrode showed a significantly greater reduction current density than the 
BP/MWNT/Py-Mb electrode (see Figure 2). In addition, the EP/MWNT/Py-Mb film required 
relatively smaller onset peroxide reduction potential compared to the Mb films on the 
BP/MWNT/Py and other electrodes (Figure 2a versus 2b-d). This suggests the possibility for the 
existence of a catalytically superior edge-edge interaction between MWNT and edge plane 
electrodes to expose a large surface area of MWNT-basal planes for high density stacking of Py 
and the protein attachment. In order to examine this, a further investigation was specifically focused 
on understanding the interaction of purely edge and purely basal plane characteristics of electrodes 
towards the MWNT/Py modification and subsequently immobilized heme protein properties as 
detailed below.   
When EP was used as the substrate electrode, the possible interaction of the edge plane sides of the 
MWNT with the electrode can expose a large portion of the MWNT sidewalls. As a result, the basal 
plane nature of MWNT sidewalls can thus allow highly dense π-π stacking of Py molecules with 
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exposed –COOH end groups. In contrast, in the case of the BP electrode, the MWNT would interact 
mainly via the sidewalls basal planes, and thereby expose only a small proportion of MWNT-basal 
plane sites to undergo π-π stacking with Py molecules. The described edge versus basal plane 
surface effects was experimentally verified by quantifying the immobilized Py molecules via 
fluorescence spectrometry. The difference in the fluorescence intensities of free Py solutions before 
and after stacking onto EP/MWNT or BP/MWNT electrode were measured (Figure 4). From this, 
it was estimated that about 3.6 nmol of Py molecules were bound to the EP/MWNT electrode and 
2.7 nmol of Py molecules were bound to the BP/MWNT electrode per unit electrode geometric area 
(in cm2). Figure 4 (inset) shows the calibration plot of standard Py solutions used in the estimation 
of MWNT/Py-bound Py molecules. 
Figure 4. Fluorescence emission spectra of Py 
solutions: a. before adding to electrodes; and 
those after π-π stacking with b. BP/MWNT and 
c. EP/MWNT electrodes. Inset shows the 
calibration plot of Py standards used for 
estimating the electrode-bound Py molecules 
based on the emission peak at 377 nm.  
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The availability of more π-π stacked Py-linkers on EP/MWNT electrode compared to the 
BP/MWNT electrode can be further expected to facilitate the covalent immobilization of larger 
number of Mb molecules on the EP/MWNT/Py electrode. This premise is indeed supported by the 
observed larger electroactive protein coverage of the Mb film on EP/MWNT/Py electrode 
compared to the other electrodes (see Table 1 and Figure 1).  
The area under the anaerobic cyclic voltammetry peak provided the electric charge (Q in coulombs) 
from which the electroactive protein amount was calculated using the equation Q = nFAΓ, where, 
n is the number of electrons transferred in the redox reaction (n = 1 for Mb-heme), F is the Faraday 
constant (96485 C), A is the electrode area (0.2 cm2), and Γ is the electroactive protein coverage in 
mol cm–2.15   Table 1 also lists the measured formal potentials and peroxide reduction current 
densities (reduction current divided by electrode geometric area) of MWNT/Py-Mb films on 
different electrodes. All modified electrodes exhibited similar formal potentials that corresponded 
to the Mb-heme redox center at pH 7.0.4,16 
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Table 1. Formal potentials, electroactive surface coverage, and reduction current densities of 
MWNT/Py-Mb films assembled on various electrodes. 
 
Electrode Eo' (V) Ґ (pmol cm–2) Reduction current density at 
0.5 V vs. Ag/AgCl, 2 mM t-
BuOOH, 1000 rpm, pH 7.0.  
(mA cm–2) 
EP –0.32 ± 0.01 237 ± 11 3.5 ± 0.2 
BP –0.32 ± 0.01 122 ± 17 2.0 ± 0.1 
GC –0.33 ± 0.01 117 ± 5 2.2 ± 0.1 
Au –0.32 ± 0.01 84 ± 5 1.8 ± 0.1 
 
The estimated Γ of Mb film attached to MWNT/Py units on the EP electrode was ~ 2-fold greater 
than that of the analogous films on BP and GC electrodes and ~3-fold better than that on the Au 
electrode. Taken together, the BP, and the smooth and relatively defect free GC and Au electrodes 
with no edge plane feature do not appear to provide any better enzyme coverage and catalytic 
properties than the EP electrode for MWNT/Py modification and protein immobilization. 
The Mb films on EP/MWNT/Py-Mb and BP/MWNT/Py-Mb electrodes were characterized by X-
ray photoelectron spectroscopy (XPS) under high vacuum conditions. The XPS data showed the 
presence of higher quantity of nitrogen element (arising from the Mb polypeptide) in the 
EP/MWNT/Py-Mb film compared to the BP/MWNT/Py-Mb film (see Figure 5). Thus, the 
fluorescence and XPS results support the observed electrochemical properties and ascertain the 
favorable edge-edge interaction of EP surface with MWNT/Py modification to allow high density 
electroactive protein immobilization via the exposed Py-linkers from MWNT-basal planes. 
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Figure 5. XPS spectra of a. 
BP/MWNT/Py-Mb and b. 
EP/MWNT/Py-Mb electrodes. 
 
 
 
 
 
 
5.4 Conclusions 
In summary, the edge plane effect in the design of a large, conductive MWNT/Py framework for 
protein immobilization and electrocatalytic applications was demonstrated. The observed catalytic 
currents suggest the role of MWNT arrangement in controlling the Py stacking and subsequent 
covalent protein immobilization more favorably on EP electrodes in comparison with BP and non-
graphitic GC and Au electrodes. To our knowledge, this is the first report that details the interaction 
of nanotube-pyrene surface chemistry with various carbon and non-graphitic electrode materials. 
Exposure of the basal plane of nanotubes for efficient pyrene compound stacking and facilitating 
high density electroactive protein immobilization on EP electrode is suggested to be crucial in 
providing high catalytic currents. Detailed kinetic studies of the designed protein electrodes are 
planned as next objectives. Overall, the outcome of this communication is expected to be significant 
in the development of efficient electrocatalytic systems for synthesis, sensing, and renewable 
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energy applications, as the nanotube-pyrene arrangements can be suitably controlled by the choice 
of underlying electrode substrate.   
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CHAPTER 6 
 
 
ENHANCED ELECTROACTIVITY AND SUBSTRATE AFFINITY OF 
MICROPEROXIDASE-11 ATTACHED TO PYRENE-LINKERS Π-Π STACKED ON 
CARBON NANOSTRUCTURE ELECTRODES 
6.1 Introduction 
The nature of protein arrangement on the surface of electrode plays an important role in controlling 
the direct electron transfer and catalytic properties.1-4  Due to this reason, the specific 
immobilization of metalloenzymes on various functionalized “nano” surfaces has gained enormous 
attention recently. Both the covalent and non-covalent attachment methods have been reported for 
attaching enzymes to carbon nanostructures for electrocatalytic applications.5-12 Among several 
redox-active proteins attached to nanotube-modified electrodes, MP-11 (an 11- amino acid heme-
iron peptide of cytochrome c) has gained enormous interests due to its small size with hydroxylation 
and peroxidase activities, similar to heme peroxidases and drug-metabolizing cytochrome P450 
enzymes.9,13  Microperoxidases are obtained from the proteolytic digestion of cytochrome c and 
retain the proximal histidine (His18) ligand of heme with the proximal imidazole coordinated to 
the heme-iron tightly at neutral pH.14
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The axial coordination of histidine to the ferric-heme has been shown to have a crucial role in the 
activity of peroxidases.15-16 Prior studies reported the immobilization of MP-11 on gold surface by 
self-assembly techniques, simple adsorption and covalent attachment onto carbon nanotubes, and 
adsorption to nonporous films of indium tin oxide or silica cavity arrays. 9,13-25  
Katz and Willner studied the direct electrochemistry of MP-11 as a self-assembled monolayer on a 
cystamine-modified gold electrode.18 Gooding et al. examined the MP-11 film bound to the free 
ends of aligned –COOH functionalized, shortened single-walled carbon nanotubes (SWNT) on the 
surface of cysteamine-layered gold electrodes.9 Dong et al. used an adsorption approach involving  
the immersion of MWNT-modified glassy carbon electrodes in MP-11 solution for 10 h.22 Another 
study utilized the covalent immobilization of MP-11 onto carbon nanotube structures by ion soft-
landing method.17 However, to our knowledge, the electrocatalytic properties of MP-11 films 
covalently linked onto pyrenyl carbon-nanostructures have not been investigated.  
6.2 Experimental 
6.2.1 Materials 
Equine heart microperoxidase-11 (MP-11) sodium salt, multiwalled carbon nanotubes (carbon 
>90% trace metal basis, outer diameter 10–15 nm, inner diameter 2–6 nm, length 0.1–10 µm, 
average wall thickness 5-15 graphene layers), 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide 
hydrochloride (EDC), tert-butyl hydroperoxide (t-BuOOH), 1-pyrenebutyric acid (Py), and N-
hydroxysuccinimide (NHS) were purchased from Sigma and used as received. High purity graphite 
electrode disks (Grade: POCO EDM-4, Average Particle Size: <4 microns) were purchased from 
EDM Inc., MN, USA. All other chemicals used were high purity analytical grade. 
 
  
85 
 
 
 
 
6.2.2 Voltammetry 
Voltammetric studies were carried out with a CHI 6017E workstation (Austin, TX, USA) at room 
temperature (25 °C) under a nitrogen atmosphere. A 3-electrode system consisting of a HPG 
electrode modified with MWNT/Py surface and attached with MP-11 as the working electrode, an 
Ag/AgCl (3 M KCl) reference electrode, and a platinum wire auxiliary electrode were used. Prior 
to surface modification, the HPG electrodes were sanded to expose a fresh surface by polishing on 
a SiC paper (P320 grit) followed by sonication in ethanol-water mixture and drying under nitrogen. 
The rotating disk voltammetry (RDV) was performed at a rotation rate of 1000 rpm using an 
EcoChemie Auto lab rotator system equipped with a motor controller unit (Metrohm Inc., USA).  
6.2.3 Preparation of MP-11 Fims on MWNT/Py Modified Electrodes.  
The procedure to prepare MWNT/Py modified electrodes and covalent MP-11 immobilization is 
similar to our group’s prior report.4 In brief, to the polished and cleaned surface of HPG electrodes 
(geometric area 0.2 cm2), a 15 µL suspension of 1 mg/mL MWNT in dimethylformamide (DMF) 
was added and allowed to dry at room temperature. Following this, a 10-µL aliquot of 1-
pyrenebutyric acid (Py, 10 mM) in DMF was added to each electrode. The electrodes were covered 
with a moisturized beaker (to avoid the Py solution from drying) and allowed for 1 hour to form 
the strong π-π stacked MWNT/Py assemblies. Then the electrodes were rinsed well with water. 
For the selective covalent attachment of MP-11 through the free amine groups (Lys-13 and N-
terminus Val-11), MWNT/Py electrodes were treated with a freshly prepared mixture of 0.35 M 3-
[3- dimethylaminopropyl]carbodiimide hydrochloride (EDC) and 0.1 M N-Hydroxysuccinimide 
(NHS) to activate the carboxylic acid surface groups of Py by reacting for 10 min. The electrodes 
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were rinsed in deionized water and subsequently 20 µL of MP-11 (1 mM in 0.1 M PBS) were 
added, and the solution was incubated for 1 hour at 4 °C to obtain MP11-aminecov films. 
6.2.4 Characterization of MP11-aminecov Films 
The characterization and surface morphological studies of the designed MWNT/Py modified 
electrodes and those attached with MP-11 films were carried out by Raman spectroscopy (Nicolet 
NXR FT-Raman module, Nd:YVO4 laser, 0.2 W, resolution 4 cm-1), Fourier transform infrared 
spectroscopy in the attenuated total reflection mode (Varian 800 FTIR, Scimitar Series), scanning 
electron microscopy (SEM), energy dispersive spectroscopy (EDS, FEI Quanta 600 field emission 
gun ESEM with Evex EDS and HKL EBSD) and transmission electron microscopy (TEM, JEOL 
JEM-2100). 
6.3 Results and Discussion 
The MP-11 used in this study was the sodium salt of microperoxidase prepared from equine heart 
cytochrome c by peptic digestion. The direct electrochemistry of MP-11 films on high purity 
graphite (HPG) electrodes modified with multiwalled carbon nanotubes (MWNT) and π-π stacked 
with 1-pyrenebutyric acid (MWNT/Py) was investigated by cyclic voltammetry. The covalent 
attachment of the two MP-11 amine groups (N-terminus Val-11 and Lys-13) to the terminal 
carboxylic acid groups of Py in MWNT/Py surface was through the amine-carboxylic acid coupling 
chemistry, similar to that reported previously (denoted as MP11-aminecov film, see Figure 1).4    
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Figure 1. Representation of the covalent immobilization of MP-11 on MWNT/Py modified HPG 
electrodes. 
 
Figure 2 shows that the characteristic D and G bands of MWNT in the Raman spectrum were shifted 
to lower frequencies as a result of π-π interaction with Py molecules.26,27 Thus, Raman spectroscopy 
confirmed the π-π stacking of Py with surface MWNT coated on HPG electrodes.  
Figure 2. Raman spectra of MWNT and 
MWNT/Py films on HPG electrodes. 
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The formation of MP-11 films on the surface of MWNT/Py electrodes was confirmed by Fourier 
transform infrared spectroscopy operated in the attenuated total reflection mode (FTIR-ATR, see 
Figures 2).  The HPG electrode and MWNT showed the carbonyl vibration peaks at 1660 cm-1 (see 
Figure 3b). The FTIR spectra were taken after each modification step on HPG electrodes (Figure 
3c-f).  The MP-11 exhibited peaks between the regions 1500-1600 and 1600-1700 cm-1, which were 
assigned to the amide-I C=O and the amide-II N-H bending frequencies typical of a peptide 
backbone.28.29 The free amine groups of MP-11 vibration bands (Lys-13 and N-terminus Val-11) 
were assigned at 1627 cm-1. The MWNT/Py modified HPG electrodes exhibited bands at 1665 cm-
1 for carbonyl stretching and a broad band at 3480 cm-1 for the –OH stretching, both are attributed 
to the end –COOH groups of the Py-linker molecules.  
Figure 3. FTIR spectra of (a) only HPG; (b) only MWNT; (c) MWNT/Py; (d) EDC-NHS treated 
MWNT/Py; (e) MP11-aminecov films; and (f) only MP-11.  
(f) 
(e) 
(d) 
(c) 
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The EDC-NHS treatment of MWNT/Py assemblies led to the disappearance of the –OH stretching 
band of –COOH (originally at 3480 cm-1) due to its conversion to N-succinimidyl groups and the 
appearance of new peaks centered at 1452 and 1769 cm-1 were attributed to C-N and C=O 
stretchings, respectively.30  The IR-spectrum obtained after the covalent bonding of MP-11 to 
MWNT/Py assemblies depicted characteristic bands for peptide amide-I and amide-II bonds in the 
region of 1500 to 1700 cm-1. Additionally the appearance of bands in the region of 3270 to 3400 
cm-1 represent the amide A and B bonds of MP-11.2 Taken together, the FTIR characterization 
confirmed the covalent immobilization of MP-11 to MWNT/Py units on HPG electrodes. 
The attachment of MP-11 to MWNT/Py units was also confirmed by surface morphological 
characterization using scanning electron microscopy (SEM, see Figure 4), transmission electron 
microscopy (TEM, see Figure 5), and energy dispersive spectroscopy (EDS, see Figure 6).  
 
Figure 4. SEM images for (A) HPG/MWNT/Py and (B) MP11-aminecov films. (C) The image of 
a bare HPG surface displaying the texture of graphite flakes is shown for comparison. 
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For the SEM imaging, polished HPG surface was only partially modified with MWNT/Py assembly 
to allow the comparison of bare HPG surface and that coated with MWNT. As can be seen from 
Figure 4, the HPG surface showing platelet like features is covered by bundles of MWNT (see 
Figure 4C and 3A). After the covalent attachment of MP-11 via amine groups, the MWNT/Py 
features were buried under the peptide film and resulted in a fiber-like texture (see Figure 4B). The 
TEM images additionally supported the inferences obtained from SEM (see Figure 5).31  The 
presence of Fe and S (possibly from the MP-11 heme and cysteinyl sulfur, respectively) identified 
in the EDS analysis further confirmed the immobilization of MP-11 on the MWNT/Py modified 
electrodes (see Figure 6).32 
Figure 5. TEM images 
for (A) MWNT/Py and 
(B) MP11-aminecov 
films (MP-11 features 
around the tubes are 
circled). 
 
 
 
Figure 6. EDS of the 
MP11-aminecov film. 
The presence of P, K, 
and Cl peaks is 
attributed to arise from 
PBS. 
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Electrochemical studies were carried out to investigate the effect of MP-11 immobilization onto 
the pyrene linkers of MWNT/Py modified electrodes with respect to the electroactive MP-11 
amount, direct electron transfer (ET) rates, and organic peroxide reduction currents. The cyclic 
voltammograms of the designed MP11-aminecov film in 0.1 M phosphate buffer saline (PBS), pH 
7.4 displayed well-defined quasi-reversible redox peaks, and indicated the direct electron transfer 
between the heme cofactor of MP-11 and the MWNT/Py modified electrode surface (see Figure 
7A a). Similarly, the control MP-11 films coated on only HPG or HPG/Py or HPG/MWNT 
electrodes showed reversible voltammograms, however, at more positive Eoʹ values due to the 
differences among the electrode surfaces that can possibly influence the MP-11 arrangements (see 
Figure 7A b-d and Table 1). In the absence of immobilized MP-11, the MWNT/Py modified 
electrode alone or only the HPG electrode did not show any redox peaks (see Figure 7B). This 
confirmed that the observed voltammetry in Figure 7A was of MP-11.  
In fact, the large double layer capacitance of MWNT/Py modified HPG electrode indicated the 
feature of high surface area [see Figure 7B(a)] and also suggested a supercapacitor property that 
has been shown for MWNT electrodes.33  By plotting the charging current densities with scan rates 
for the HPG/MWNT/Py and bare HPG electrodes, the capacitance values of each electrode from 
the slopes of the resulting plots (see Figure 8) was obtained.34  By this procedure, it was determined 
that the capacitance of HPG/MWNT/Py was 1066 µF cm-2 and that of the polished HPG surface 
was 367 µF cm-2. This indicated that the MWNT/Py modification on HPG electrode offered an ~3-
fold greater electroactive surface area than the unmodified HPG electrode. 
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Figure 7. (A) Background subtracted cyclic voltammograms of a. MP11-aminecov, b. MWNT-
MP11 (EDC/NHS activated MWNT, but no pyrene linker), c. HPG/Py-MP11 with no MWNT, and 
d. HPG/MP11 with no Py and MWNT at 0.7 V/s in pH 7.4, PBS. (B) Cyclic voltammograms of a. 
MWNT/Py modified electrode and b. only HPG electrode with no MP-11 film. 
 
Figure 8. Current density versus 
scan rate plot for the charging 
currents measured for (a) 
HPG/MWNT/Py electrode and 
(b) polished HPG electrode in the 
absence of immobilized MP-11. 
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The cathodic (Epc) and anodic (Epa) peak separation (∆Ep) with increasing scan rate of the MP11-
aminecov film was used to calculate the standard ET rate constant (ks) by the Laviron’s method.35,36  
A ks value of 4.6 ± 0.2 s-1 was obtained for the designed MP11-aminecov film. The electroactive 
surface concentration (Γ) of MP11-aminecov film was calculated by integrating the area of the 
reduction or oxidation peak (since the peak current ratio was close to unity).4,36,37  The MP11-
aminecov film exhibited an ~ 2-fold higher electroactive coverage than the MWNT-MP11 film 
(EDC/NHS activated MWNT) without the pyrene linker [see Figure 7A(b)], and ~ 3 to 4-fold 
enhancement in Γ than the films of HPG/Py-MP11 with no MWNT [see Figure 7A(c)] and 
HPG/MP11 with no Py and MWNT [see Figure 7A(d)] (see Table 1 for all values). This property 
confirms the unique role of the pyrene linkers in facilitating higher density covalent immobilization 
of MP-11 and the associated large electroactive enzyme coverage in the MP11-aminecov film over 
other control films.  
 Table 1. Comparison of the electroactive MP-11 amounts on MWNT/Py electrodes with control 
films and the reported myoglobin-aminecov film. 
  
MP-11 Film Γ / pmol cm-2 Ref. 
MP11-aminecov 
HPG/MWNT-MP11 
HPG/MP11 
HPG/Py-MP11 
2385 ± 103 
1250 ± 66 
619 ± 28 
746 ± 30 
 
This study 
myoglobin-aminecov 300 ± 60 4 
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Furthermore, an 8-fold enhancement in Γ was obtained for the MP11-aminecov film when compared 
to a myoglobin film (-0.35 V vs Ag/AgCl, Table 1) attached similarly via surface amino groups on 
MWNT/Py modified electrodes (denoted as myogl obin-aminecov, see Table 1).4 The electroactive 
coverage of MP-11 films on the modified electrodes suggests the formation of multilayer films, 
with a highly possible electron self-exchange phenomenon occurring between adjacent MP-11 
heme centers.21,23,36  
The electrocatalytic property of the MP11-aminecov film and other control films was investigated 
by monitoring the reduction of tert-butyl hydroperoxide (t-BuOOH) to tert-butanol (t-BuOH). The 
larger electroactive MP-11 in the MP11-aminecov film led to a 1.5 to 2-fold greater catalytic 
reduction current density of this film over control MP-11 films (see Figure 9, Table 2). Thus, the 
enhancement effect of pyrene linkers on both the electroactive coverage and the electrocatalytic 
currents of immobilized MP-11 in the MP11-aminecov film can be understood. The currents were 
measured at the plateau region at -0.5 V vs Ag/AgCl, which is a high enough overpotential region, 
where the interfacial ET-rate is presumed to be not rate limiting.10,11,36 The reduction currents were 
subtracted for the small background currents (≤ 5% of the catalytic current) from the respective 
electrodes with no immobilized MP-11 films (i.e., MWNT/Py, MWNT, HPG/Py, and only HPG; 
see Figure. 11b illustrates the background reduction currents from the HPG/MWNT/Py electrode). 
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Figure 9. Electrocatalytic t-BuOOH (4.8 mM) 
reduction currents at 1000 rpm in PBS (pH 7.4), 
25 oC, catalyzed by a. MP-aminecov, b. MWNT-
MP11 (EDC/NHS activated MWNT, but no 
pyrene linker), c. HPG/Py-MP11 with no MWNT, 
and d. HPG/MP11 with no Py and MWNT. 
  
 
 
 
Table 2. Contribution of pyrene linker in enhancing the catalytic reduction currents of MP11-
aminecov film over control films. 
 
Enzyme film type Eoʹ (in V) vs 
Ag/AgCl 
Catalytic Current Density (mA cm-2) 
(at -0.5 V vs Ag/AgCl) 
MP11-aminecov -0.36  (± 0.01) 7.5 ± 0.4 
HPG/MP11 
(no MWNT and Py-linker) 
-0.28  (± 0.01) 3.4 ± 0.2 
HPG/Py-MP11 
(no MWNT) 
-0.33  (± 0.01) 3.6 ± 0.1 
HPG/MWNT- MP11 
(no  Py-linker) 
-0.32 (± 0.03) 4.8 ± 0.2 
myoglobin-aminecov (Ref. 4) -0.35 (± 0.02) 4.1 ± 0.3 
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The t- The t-BuOOH reduction currents catalyzed by the MP11-aminecov film, versus the applied 
potential for increasing t-BuOOH concentrations, are shown in Figure 10.  
Figure 10. Reduction currents versus t-BuOOH 
concentration at 1000 rpm catalyzed by the MP11-
aminecov film in pH 7.4 PBS for a. 0.8, b. 1.6, c. 3.2, 
and d. 4.8 mM t-BuOOH. 
 
 
 
 
The catalytic reduction current density (current divided by the electrode geometric area) versus the 
concentration of t-BuOOH present in solution is shown in Figure 11a. The small background 
reduction currents from the MWNT/Py electrodes with no MP-11 film are shown in Figure 11b. 
 
Figure 11. Catalytic current densities with t-
BuOOH concentration at 1000 rpm for the 
designed (a) MP11-aminecov film and (b) 
MWNT/Py electrode in the absence of attached 
MP-11 in pH 7.4, PBS, 25 oC. 
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The designed MP11-aminecov film exhibited a high electrocatalytic activity with a current density 
of 7.5 mA cm-2 towards an organic peroxide reduction. The current density is greater by about 2–
fold than the myoglobin-aminecov films.4  This feature can be attributed to the small size of MP-11 
heme peptide favoring high density surface concentration compared to the relatively large 
myoglobin protein. More interestingly, the apparent Michaelis-Menten constant (Kmapp) obtained 
from the Michaelis-Menten fit of reduction current density plot (Figure 11a) of the designed MP11-
aminecov film (Kmapp = 1 mM) is 12-fold smaller than that observed by us for the myoglobin-
aminecov film (Kmapp = 12 mM).4 This suggests the stronger affinity of short MP-11 peptide by the 
designed covalent strategy over the similarly prepared large myoglobin protein film towards an 
organic peroxide substrate.  
6.4 Conclusions 
The results presented demonstrate that the π-π stacking of pyrene linkers with carbon nanotubes 
offers enhanced electroactive redox protein molecules and catalytic currents probably by retaining 
the innate electronic properties of MWNT and additionally by the presence of a large number of 
stacked pyrene units for high density, stable covalent enzyme immobilization. Furthermore, the 
findings above suggest a new potential direction in achieving high electrocatalytic activities of a 
large, fragile, redox-center buried, or otherwise difficult to study metalloenzymes by mutating them 
into small catalytically active redox domains to effectively connect with electrodes. 
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CHAPTER 7 
 
SUMMARY 
 
Analytical methodologies to facilitate the drug development process have been one of the foci of 
the research outlined in this dissertation. Optical approaches for cancer target identification and 
electrochemical approaches for preclinical drug screening and quality assurance have been the 
subject of exhaustive study.  Under the theme of bio-electrocatalysis, nanostructure architectures 
for catalytic applications were also investigated. Furthermore, numerous analytical insights into 
biomedical and bioelectronics have been gained in these studies.  The contributions made to 
analytical chemistry are summarized below. 
In one study (see Chapter 2), surface plasmon resonance micro array imaging technique was 
successfully used to detect targeted cancer protein-protein interactions and to study small molecule 
inhibition of these interactions in a label-free manner. A rapid optical microarray imaging approach 
which includes the use of a mass sensor for validation was investigated for anti-cancer drug 
screening at specific cancer protein-protein interface targets with binding kinetics. SPRi 
demonstrated a 3.5-fold greater specificity for interactions between MDM2 and wild type p53 over 
a non-specific p53 mutant in a real time microfluidic analysis.  Significant percentage reflectivity 
changes (Δ%R) in the SPRi signals and molecular level mass changes were detected for both the 
MDM2-p53 interaction and its inhibition by the small molecule Nutlin-3 drug analog known for its
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 anti-cancer property. Additionally, it was demonstrated that synthetic, inexpensive binding 
domains of interacting cancer proteins are sufficient to screen anti-cancer drugs by an array-based 
SPRi technique with excellent specificity and sensitivity. This imaging array, combined with a 
mass sensor can be used to study any protein-protein interactions and to screen for small molecules 
with the desired binding and potency. 
In another study (see chapter 3), a new method for pre-clinical drug screening was demonstrated 
by designing a one-step, rapid microsomal electrochemical bioreactor technology for drug 
metabolite synthesis and inhibition. In order to design a green microsomal bioreactor on suitably 
identified carbon electrodes, it is important to understand the direct electrochemical properties at 
the interfaces between various carbon electrode materials and HLM. The novelty of this work was 
on the investigation of directly adsorbed HLM on different carbon electrodes with the goal to 
developing a simple, rapid, and new bioanalytical platform of HLM useful for drug metabolism 
and inhibition assays. These bio-interfaces were designed in this study using a one-step adsorption 
of HLM directly onto polished BPG, EPG, GC, or HPG electrodes. The estimated direct electron 
transfer rate constant of HLM on the smooth GC surface was significantly greater than that of the 
other electrodes.  On the other hand, the electroactive surface coverage and stability of microsomal 
films were greater on a rough EPG and HPG electrode surface compared to smooth GC and less 
defective hydrophobic BPG surfaces.  The presence of significantly higher oxygen functionalities 
and flatness of the GC surface was attributed to promote faster ET rates of the coated layer of the 
thin HLM film compared to the EPG, BPG, and HPG electrodes. The cytochrome P450-specific 
bioactivity of the liver microsomal film on the catalytically superior, stable HPG surface was 
confirmed by monitoring the electrocatalytic conversion of testosterone to 6β-hydroxytestosterone 
and its inhibition by the CYP-specific ketoconazole inhibitor. The identification of optimal HPG 
and EPG electrodes to design biologically active interfaces with liver microsomes was suggested 
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to have immense significance in the design of one-step, green bioreactors for stereo-selective drug 
metabolite synthesis and for drug metabolism and inhibition assays. 
In a third study (see chapter 4), single drop electroanalysis was demonstrated as a cost-effective 
and instant analytical strategy for the quality assurance of active pharmaceutical ingredients in 
drugs.  Single drop electroanalytical measurements of pharmaceutically and biologically relevant 
compounds using screen printed electrodes modified with MWNT-COOH as the sensor surface 
were studied. Acetaminophen, nicotine, ascorbic acid, and the reduced form of nicotinamide 
adenine dinucleotide were detected in a single drop of solution. It was shown that combined polar 
and nonpolar interactions of analytes with –COOH functional groups and large surface area of 
MWCNT, respectively, allow highly sensitive analyte detection with wide dynamic range. Smaller 
analytes could bind to a significantly greater number of sensor sites than bulkier analytes and offer 
better detection sensitivity.  Results suggested that sensitivity is controlled by predominant 
nonpolar interactions which an analyte can undergo with the MWCNT-COOH SPE sensor surface, 
whereas the limit of detection was controlled by the extent of polar interactions between an analyte 
and the sensor surface, facilitating interfacial charge transport and an electrochemical signal output. 
This could be a likely reason for why sensitivity does not need to always correlate with lower 
detection limits as variations in the interfacial interactions are critical. Application of the designed 
single drop method to a real sample was validated by estimating the amounts of acetaminophen, 
nicotine, ascorbic acid, and NADH in commercially available pharmaceuticals with excellent 
recovery.  
In a final study (see chapters 5), it was shown that edge-to-edge interaction between carbon 
nanotubes and edge plane electrodes plays an important role in exposing a large proportion of the 
basal planes of the CNTs to allow enhanced π-π stacking of a pyrenyl compound and subsequent 
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high density protein immobilization yielding large electrocatalytic currents. In the same way (see 
chapter 6), an exceptionally large electroactively connected MP-11 with strong affinity for an 
organic peroxide and offering a high electrocatalytic reduction current density of 7.5 mA cm-2 has 
been achieved for the first time. Insights into the multiwall carbon nanotube arrangement in 
controlling the pyrene stacking and subsequent covalent protein immobilization was significant for  
high efficient catalytic and sensing applications in modern bioelectronics. 
These studies suggest several new optical and electrochemical approaches for high throughput drug 
screening and bio-inspired, stable nanostructure electrocatalytic platforms for green energy 
generation.  The applicability of SPRi technology for array based detection of cancer protein 
interactions with binding kinetics can provide new insights to cancer research. Also, the simple 
construction of potential driven microsomal electrodes for drug metabolite synthesis, compared to 
conventional biological assays will have a positive impact on pre-clinical drug screening industry.  
Additionally, controlled and stable immobilization of biologically relevant enzymes onto 
nanostructured electrodes may generate new opportunities towards the development of high 
efficient biocatalytic systems.
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